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ABSTRACT 
Type 1 diabetes (T1D) is a chronic disorder in which the cells of the immune 
system mediate selective destruction of the insulin-producing β-cells in the islets 
of Langerhans in the pancreas. CD4+ effector T cells, including Th1 and Th17 
cells, are crucial mediators during disease development. Therefore, therapeutic 
strategies against T1D should target both T cell subtypes. The mechanisms 
underlying the control of Th1 cells are well-defined, but those operating 
modulation of Th17 cells remain largely unknown due to the fact that Th17 cells 
are plastic and can drive the disease as convertible (Th17 to Th1) or stable T 
cells. To overcome these limitations, a tolerance induction model was developed 
to analyze the mechanisms underlying modulation of plastic Th17 cells. Indeed, 
upon induction of tolerance, convertible (Th17 to Th1) cells displayed 
downregulation of the chemokine receptor CXCR3 that was associated with 
diminished T-bet expression, leading to retention of the cells in the spleen and 
inhibition of trafficking to the pancreas. In contrast, stable Th17 cells 
downregulated RORγt but increased FasL expression and died by apoptosis 
under the same antigen-specific tolerance. Thus, the final signature transcription 
factor shapes the mechanism of tolerance in plastic Th17 cells. These findings 
suggest that effective strategies against T1D will require regimens that could 
drive both mechanisms of tolerance to overcome the disease.  
A core feature of autoimmune diabetes is the loss of the majority of insulin-
producing β cells. Therefore, reversal of overt T1D requires restoration of β-cell 
mass in addition to effective control of islet inflammation. It has been established 
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that β-cell turnover relies on self-replication of pre-existing β-cells; however, the 
diabetic state is tightly associated with a striking decrease of the islet endothelial 
cells, leading to poor β-cell survival and function. Given that the endothelial 
progenitor cells (EPCs) reside in the bone marrow and the number of EPCs 
significantly decreased in human and mice with T1D, we devised a combination 
treatment regimen in which bone marrow transfer was coupled with an antigen-
specific tolerance therapy, and tested it against overt T1D. Indeed, transfer of 
whole bone marrow or fractioned EPCs gave rise to islet endothelial cells, which 
facilitated regeneration of endogenous β-cells and normalization of glucose 
levels. Therefore, this work provides a new avenue in design of future therapies 
against T1D by emphasizing the importance of re-establishing a functional 
microvascular network and the symbiotic relationship between endothelial and β-
cells in the islet of Langerhans. 
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1. ANTIGEN TARGETS IN AUTOIMMUNE DIABETES 
Type 1 diabetes (T1D) is caused by immune-mediated selective destruction of 
the insulin-producing β cells in the pancreatic islets of Langerhans. The majority 
of the immune cells that infiltrate into the islets are T lymphocytes recognizing β-
cell derived peptide antigens (Lieberman and DiLorenzo, 2003). Therefore, 
comprehensive understanding of the disease pathogenesis would require 
thorough characterization of the antigen types and their corresponding T cells. 
Herein, recent findings regarding identified antigenic targets involved in T1D are 
summarized in this section. 
The presence of autoantibodies is an important indicator for prediction of T1D 
onset in human subjects (Orban et al., 2009). Approaches using autoantibodies 
for immunoprecipitation allowed for identification of various autoantigens involved 
in T1D, such as preproinsulin/insulin, glutamic acid decarboxylase (GAD), 
insulinoma antigen-2 (IA-2), and islet-specific glucose-6-phosphatase catalytic 
subunit-related protein (IGRP). A vast number of studies aiming at characterizing 
the structure and function of the islet antigens have suggested a prominent role 
of the insulin and GAD antigens in the priming and augmentation of T cell 
autoreactivities. Therefore, this section will mainly discuss insulin and GAD 
antigens as well as their cognate T cells. Other autoantigens, which were 
extensively reviewed elsewhere (Arvan et al., 2012; Roep and Peakman, 2012), 
will not be a major focus in this section.  
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A. Insulin 
Recent findings have suggested that the mean level of autoantibodies against 
insulin correlates with the age of the first presentation of T1D in susceptible 
children (Steck et al., 2011). In addition, insulin autoantibodies were detected 
before the onset of T1D and were used to predict the development of the disease 
(Gottlieb and Eisenbarth, 2002). In the non obese diabetic (NOD) mouse model, 
the presence of insulin autoantibodies is detected between 4 and 8 weeks of 
age, a time point preceding evident insulitis. Collectively, these findings suggest 
that insulin is one of the major antigens involved in the initiation of the disease.  
The prominent role of the insulin reactivity in T1D pathogenesis is supported by 
several lines of studies. Manipulation of the insulin promoter by variable number 
of tandem repeats polymorphism or mutations resulted in reduced insulin 
expression in the thymus, leading to a breakdown of insulin self-tolerance 
(Bennett et al., 1995; Vafiadis et al., 1997). NOD mice express two genes coding 
preproinsulin, insulin 1 and insulin 2. Insulin 1 is exclusively expressed in the islet 
whereas insulin 2 is expressed both in the thymus and the islet. Genetic ablation 
of insulin 1 in NOD mice diminished T1D onset, while a complete knockout of 
insulin 2 accelerated the disease (Moriyama et al., 2003; Thebault-Baumont et 
al., 2003). These results support the notion that autoreactive T cells recognizing 
insulin 1-coding protein antigens are able to escape thymic purging and respond 
to the local antigens in the islet. Furthermore, a recent study revealed that the 
expression of insulin 2 by thymic medullar epithelial cells (mTECs) is critical for 
sustaining self-tolerance to insulin reactive T cells. In fact, selective deletion of 
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insulin 2 in mTECs of insulin 1-/- C57BL/6 mice induced robust diabetes (Fan et 
al., 2009), suggesting a potentially strong reactivity of T cells to insulin 2-coding 
antigens in the islet when the central surveillance machinery is defective.  
The antigenic property of the insulin protein antigen is predominantly represented 
by the B: 9-23 epitope. NOD mice with an ablation of both insulin 1 and insulin 2 
but expressing a bioactive insulin gene encoding a mutant B: 9-23 epitope are 
diabetes-resistant (Nakayama et al., 2005). These findings suggest that B: 9-23 
autoreactivity may be up-stream of other pathogenic T cell responses. 
Importantly, the mouse B: 9-23 sequence is identical to the human counterpart, 
and T cells from patients with a recent onset of T1D also recognized this epitope. 
In NOD mice, a group of unique diabetogenic T cells recognizing the free B: 9-23 
peptide but not the same peptide fragment processed from the insulin protein has 
been identified (Mohan et al., 2010). This finding provides a leading hypothesis 
regarding the formation of insulin autoreactivity in NOD mice, which will be 
discussed in detail in the second section of this chapter. In addition, the 
prominent role of the B: 9-23 peptide is highlighted by its therapeutic potential in 
antigen-specific strategies against T1D in human and NOD mice (Clemente-
Casares et al., 2012), which will be elaborated in the third section of this chapter.  
 
B. Glutamic acid decarboxylase 
Identification of GAD as an autoantigen in T1D can be traced back to studies 
using immunoprecipitation assays, in which solubilized rat islets were incubated 
with sera from newly diagnosed T1D patients. Indeed, autoantibodies in the sera 
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pulled down a 64 KD protein (Baekkeskov et al., 1982), which was identified as 
GAD in a subsequent study (Baekkeskov et al., 1990). Based on these findings, 
a system for detection of autoantibodies against GAD65 was developed (Grubin 
et al., 1994).  
There are several unique characteristics of GAD65-associated antigens relative 
to other islet antigens, including insulin. First, GAD antigens are not associated 
with the dense core of the insulin secretory granules (Sorenson et al., 1991), and 
are synthesized in the β-cell cytosol rather than the ER (Uchizono et al., 2007; 
Wicksteed et al., 2007). Second, GAD antigens may be more likely involved in 
the advanced disease stages compared to the insulin antigens, which are 
associated with the initial stages of the disease (Chao et al., 1999). Furthermore, 
unlike depletion of insulin 1 in NOD mice, GAD65 knockout NOD mice were not 
protected from the disease (Yamamoto et al., 2004). However, diabetes was 
diminished in a NOD mouse model with inhibition of GAD65 expression in the 
islet by anti-sense RNA (Jun et al., 2002). These results suggested a regulatory 
rather than pathogenic role of GAD65-reactive T cells in the periphery. In fact, 
transfer of spleen cells from NOD.GAD65-/- mice to NOD.scid recipients 
significantly delayed the disease onset relative to the transfer of NOD.GAD65+/+ 
cells (Kanazawa et al., 2009). To date, most of the T cell clones recognizing 
different GAD65-derived peptides displayed inhibitory effects against 
diabetogenic responses, which will be discussed in detail in the third section of 
this chapter. 
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C. Concluding remarks 
Although the list of the autoantigens involved in T1D is ever growing (Table 1), 
the precise nature and identity of the target antigens still remain to be 
determined. The paucity of this information is due to the vast diversity of the 
antigen repertoire and the temporal distribution of the antigens during different 
disease stages (so called epitope spreading). Other technical limitations, such as 
the lack of I-Ag7 expression on β-cells and the low number of the primary β-cells 
for in vitro examination, made it difficult to identify the natural peptides bound to I-
Ag7. A previous study employed insulinoma cell lines expressing I-Ag7 to identify 
their MHC-peptidome (Suri et al., 2008). Using this approach, T cells directed to 
various proteins of the secretory granules, such as chromogranin and 
secretogranin, have been identified (Suri et al., 2008). One caveat of this strategy 
is that it may only be able to identify epitopes with a high affinity to I-Ag7. To 
circumvent this limitation, the same group developed a computational program to 
predict the peptides bound to I-Ag7 as well as those to the human MHCII 
molecule HLA-DQ8 (Chang et al., 2007). Further examination of the functional 
activities of the corresponding T cells would undoubtedly further our 
understanding of the T cell-driven events during T1D pathogenesis.  
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Table 1. Major antigen targets in type 1 diabetes. 
 
Adapted from Roep et al., 2012 
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2. INITIATION AND PROGRESSION OF AUTOIMMUNE DIABETES 
Autoimmune diseases, including T1D, are driven by intertwined cellular and 
molecular pathways incorporating genetic predisposition, environmental triggers 
and breakdown of self-tolerance (Atkinson, 2012). Autoimmune diabetes involves 
destruction of insulin-producing β-cells by immune attacks mainly mediated by 
CD4+ and CD8+ T cells. In human and the NOD mouse model, the immune 
insults (so called insulitis) in the islets of Langerhans are observed long time 
before the ultimate critical loss of β-cell mass that leads to hyperglycemia (Jeker 
et al., 2012). In this regard, the disease can be generally divided into two stages: 
1. Initiation of immune attacks that is somehow chronic, benign and controlled. 2. 
Progression of destructive insulitis that overcomes the regulatory mechanisms 
and specifically destroys pancreatic β-cells. In the human context, genetic 
predisposition (Steck and Rewers, 2011) and environmental triggers (Knip and 
Simell, 2012) would undoubtedly play an important role in T1D pathogenesis, 
and a better understanding of these factors would provide insights into disease 
prediagnosis and prevention. However, the NOD mice, which share identical 
genetic materials and very similar, if not the same, housing environment, would 
be invaluable tools for analyses of immunological events that initiate, culminate 
and finally demolish β-cells. Herein, the recent findings regarding the initiation 
and propagation of autoimmune diabetes, including the potential environmental 
triggers and the critical immunological events, are summarized. 
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A. Environmental triggers 
It has been viewed that pathogen infections are important environmental factors 
that can influence the disease course by altering immune function and/or directly 
acting on β-cells. For example, local inflammation can induce β-cell death, 
leading to a pronounced release of β-cell antigens, which may accelerate the 
priming of autoreactive T cells (Filippi and von Herrath, 2008). Molecular mimicry 
and cross-presentation of viral epitopes may initiate and enhance T cell 
responses. Nevertheless, the altered function of APCs by pathogen infections 
permits antigen presentation to self-reactive T cells in an inflammatory rather 
than a tolerogenic condition. The role of viral triggers in T1D is further supported 
by the fact that the IFIH1 gene involved in anti-viral immunity has been 
associated with a decrease of disease risk (Nejentsev et al., 2009), and that 
enteroviruses have been isolated from patients with a recent onset of T1D (Filippi 
and von Herrath, 2008). However, it should be noted that the type and timing of 
the viral infection might protect or accelerate the disease development (Filippi 
and von Herrath, 2008). In fact, it is believed that a lower hygiene standard is 
associated with a lower incidence of diabetes. In support of this notion is the fact 
that Western countries generally have a higher diabetes incidence (Filippi and 
von Herrath, 2008). Therefore, certain pathogen infections may protect T1D by 
shaping the host immune responses. For example, NOD mice infected by 
Schistosoma mansoni were protected against diabetes with a shift of the Th1 to 
Th2 responses, a mechanism also observed in various protective antigen-
specific treatments (Zaccone et al., 2003). In addition, Salmonella typhimurium 
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infection reduced disease incidence possibly through influencing dendritic cells 
and T cell trafficking to the pancreas (Raine et al., 2006). Notably, the same type 
of bacteria can be detrimental or protective in different autoimmune diseases 
depending on the type of the immune response driving the disease. The most 
relative evidence is two studies showing that the intestinal segmented 
filamentous bacteria protected against T1D (Kriegel et al., 2011), but 
exacerbated rheumatoid arthritis (Wu et al., 2010). Therefore, anti-viral immunity 
should be viewed as an integrated part of the autoimmune responses. In this 
regard, interesting questions could be raised, such as whether exhaustion of 
CD8 T cells during chronic viral infection would dampen the pathogenic function 
of the β-cell-reactive T cells or whether the APCs bearing viral antigens could 
migrate into thymus and affect the selection of the autoreactive T cells. 
Nevertheless, more analyses are needed to further define the role of pathogen 
infections in triggering autoimmune diabetes, and the answer would probably 
never be definite because of the broad diversity of the pathogens types and the 
related T cell responses. 
It is understandable that pathogen infection is not indispensible in triggering T1D 
simply because not every individual would have the same chance for exposure. 
In fact, endogenous triggers, especially the commensal triggers have gained 
considerable attention and provide a new avenue for understanding how the 
interaction between the gut microbiota and the immune system would influence 
the course of autoimmune diabetes. The fact that initiation of cell infiltration into 
the islets occurs at the week of weaning in NOD mice indicates that alterations in 
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gut microbiota may be a part of the early events during T1D pathogenesis. 
Indeed, the reciprocal role between gut microbiota and the immune system and 
its influence in the development of T1D has been highlighted by a study showing 
that germ free female NOD mice displayed an accelerated disease onset 
compared with those housed under SPF conditions (Wen et al., 2008). In 
addition, removal of the commensal bacteria permitted a robust disease 
development in the diabetes-resistant male mice (Wen et al., 2008). These 
results suggest a critical role of the intestinal microbiota in alleviating the disease 
progression. Furthermore, MyD88-deficient mice, which are normally protected 
from T1D, developed robust disease under germ free conditions (Wen et al., 
2008). These results suggest that the intimate interaction between commensal 
microbiota and innate immune cells plays an important role in modulation of T 
cell priming because removal of commensal microbiota nullified MyD88-
dependence of the innate cells for priming T cells. However, whether commensal 
ablation results in pronounced MyD88-independent pathway or aberrant APC 
functions is not clear. Furthermore, colonization of a consortium of bacterial 
species to germ free MyD88-/- mice significantly attenuated the disease, and the 
MyD88-/- mice displayed specific changes in the composition of commensal 
microbiota (Wen et al., 2008). These data clearly provided a new perspective in 
the pathogenesis of T1D, although the precise mechanism of induction of local 
tolerance by the microbiota remains to be elucidated.  
Importantly, children that develop T1D also possess a different microbiome 
compared with the control children (Giongo et al., 2011). In addition, human 
12 
 
diabetic subjects displayed upregulation of zonulin, a protein associated with 
increased intestine permeability (Sapone et al., 2006), suggesting that that loss 
of the intestine barrier function may lead to a switch from tolerance to activation 
in response to gut non-self antigens. As such, gut antigens and/or APCs bearing 
gut antigens may circulate to pancreas or the draining lymph nodes, leading to 
priming of β-cell reactive T cells. However, evidence regarding how β-cell 
reactive T cells would recognize gut non-self antigens still lacks. In addition, it 
has been established that β-cell reactive T cells express gut-specific homing 
receptors (Paronen et al., 1997),  and the same molecules can home to both 
pancreas and gastrointestinal tract (Vaarala, 2000). Because the pancreatic 
draining lymph node (PLN) is a preferred site for cell trafficking from the 
peritoneal cavity, it is possible that the inflammatory state of the gut environment 
could affect the activation state of APCs in the pancreatic lymph nodes. Another 
connection between pancreas and the gut environment is the omentum, which 
may serve as a site for T cell response to trapped peritoneal antigens (Rangel-
Moreno et al., 2009). These findings clearly suggested a potential role of the gut 
microenvironment in regulation of the immune responses in pancreas. However, 
important and intriguing questions remained to be answered with more powerful 
analytic tools. For example, it is not clear whether female NOD mice that 
eventually develop diabetes would display increased intestinal permeability at an 
early age relative to those who share the same cage but are resistant to clinical 
diabetes or whether the loss of the gut barrier function is due to intrinsic factors, 
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such as changes in the composition of commensal microbiota, or needed to be 
triggered by a pathogen infection.  
 
B. Initial immunological events in T1D 
The most important genetic determinant of T1D incidence in human and mice is 
the major histocompatibility complex (MHC). Furthermore, the fact that disease 
concordance between monozygotic twins is about 50% suggests a critical role of 
the immune system in determining the outcome of the disease independently of 
genetic and environmental triggers. For example, islet resident dendritic cells 
(DCs) are heavily loaded with β-cell-derived peptide antigens under a 
physiological condition, and neither β-cell death nor local inflammation affected 
the presentation of the peptide/MHC (pMHC) complex to the T cells.  Thus, it is 
likely that these islet DCs migrate to the draining lymph nodes where they 
present antigens to circulating T cells (Calderon et al., 2008). However, it is not 
clear that whether islet antigens can be directly released to the draining lymph 
node and captured by the PLN DCs. In this regard, a model that can specifically 
label and track islet DCs would be valuable in determining the initial site of the T 
cell priming and the environmental cues, if any, driving the migration of DCs. 
However, this would be very difficult due to a lack of congenic marker for islet 
DCs because they seem to have a typical immature phenotype despite a 
relatively high expression of B7-1 (Calderon et al., 2008).  
Another strategy to dissect the initial events in T1D is to monitor the islet 
transcriptional profiling throughout the disease pathogenesis. A study focusing on 
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the transition of innocuous to destructive insulitis demonstrated that the 
expression of natural killer (NK)-cell-specific genes and the percentage of these 
cells increased in the more aggressive diabetogenic TCR transgenic strain 
(Poirot et al., 2004). In addition, entry of antigen-specific T cells into the islet was 
observed as early as 24h after intravenous transfer and was associated with 
upregulation of chemokines and adhesion molecules, which is needed for 
subsequent entry of non-specific T cells (Calderon et al., 2011). Furthermore, the 
entry of antigen-specific T cells induced rapid changes in the expression of a 
group of interferon-inducible genes in the islets (Calderon et al., 2011). Indeed, 
upregulation of type I interferon (IFN-I)-inducible genes was observed in the PLN 
at the 4 and 6 weeks of age in both NOD and NOD.BDC2.5 TCR transgenic 
mice, and blockade of IFNα receptor 1 in 2 or 3-week old mice significantly 
delayed disease onset (Li et al., 2008). More importantly, a study used reliable 
islet isolation techniques and transcriptional profiling assays to examine the gene 
expression changes in the islets throughout the disease pathogenesis in NOD 
mice (Carrero et al., 2013). This study pinpointed a unique IFN-I signature in the 
islets of all the NOD female mice at 4-6 weeks of age, a time point preceding T 
cell activation (Carrero et al., 2013). However, the causative association between 
upregulation of IFN-I and entry of T cells is not known.  
The early entry of CD4+ T cells is one of the most important events during the 
initial steps of T1D pathogenesis. It is believed the first entry of T cells should be 
β-cell-antigen specific, but the actual specificity of these T cells is not known. 
Insulin is considered one of the initiating autoantigens, and it has been shown 
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that the islet DCs bearing antigens derived from secretary granules containing 
insulin protein or peptides (Mohan et al., 2010). Two types of insulin-reactive T 
cells have been identified: the type A T cells recognize both insulin protein and/or 
the B: 9-23 peptide, while the type B T cells only recognize soluble B: 9-23 
peptide when offered exogenously (Mohan et al., 2010). Therefore, the type A T 
cells are readily being negatively selected in the thymus in that the thymic 
epithelial cells express insulin protein. However, the type B T cells are able to 
escape thymic purging, and respond to a low concentration of the insulin peptide 
antigen in the islets (Mohan et al., 2010; Mohan and Unanue, 2012). The free 
peptide antigen is indeed available in the β-cell secretory granules and the local 
DCs are able to capture these granules. Therefore, these type B T cells are likely 
among the first entry of the T cells that infiltrate into the islet. Analysis of these 
unique diabetogenic T cells using a TCR transgenic mouse model would 
certainly further our understanding of the initial T cell-driven events in T1D. 
 
C. Transition from insulitis to β-cell destruction 
A mysterious and key question in the field of T1D is how the initial benign 
immune insults progress into destructive insulitis that eventually results in 
hyperglycemia. In the clinical perspective, this is of great importance due to the 
difficulty for prediction and prevention of the disease at a very early stage. 
Therefore, perhaps a better and more practical way to rescue the vulnerable β-
cells is to block the progression of invasive insulitis. The fact that every NOD 
mouse, regardless of female or male, develops insulitis but varies in the 
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incidence of clinical diabetes provides a good starting point for this line of 
researches. The question then has become if we have a cage of 10 young 
female NOD mice, can we do a simple experiment to predict which 6-8 will 
develop hyperglycemia at 20 or 30-week old of age? A recent study utilized 
magnetic resonance imaging (MRI) to scan the pancreatic region of female NOD 
mice at the prediabetic stage and found that the mice that eventually developed 
clinical disease had a significantly higher T2 value as early as 6-week old (Fu et 
al., 2012). Thus, it appears that the occurrence of clinical diabetes has already 
been determined in a relatively early stage rather than a late outcome after a 
long term fight between pathogenic and regulatory elements. More specifically, it 
is possible that some early pathogenic events have precipitated and need to 
overcome the defensive mechanisms to drive the clinical disease, which means 
that, there is no need for a secondary hit, such as a pathogen infection, or late 
development of certain pathogenic cells for determinism of diabetes incidence. In 
support of this, this study performed microarray analyses to screen and compare 
the changes of gene expression in the pancreatic islets between diabetes-prone 
and –resistant mice. Indeed, these assays revealed an upregulation of the 
complement receptor of the immunoglobulin superfamily (CRIg) in the latter 
group (Fu et al., 2012). The authors subsequently confirmed the protein 
upregulation of CRIg on islet macrophages and demonstrated that inhibition of 
CRIg in 3-week old mice accelerated disease onset (Fu et al., 2012). It should be 
noted that CRIg is among a group of upregulated genes in the diabetes-resistant 
NOD mice, which are potentially protective genes of diabetes (Fu et al., 2012). 
17 
 
Therefore, thorough characterization of these genes should provide valuable 
insights into the critical elements attenuating disease incidence. Indeed, the 
authors suggested that many of these genes are associated with macrophage 
functions, which may dampen T cell responses by timely clearance of apoptotic 
β-cell debris. A more desired result would be to have some “biomarkers” that 
readily distinguish the diabetes-prone and –resistant NOD mice. 
The chronic nature of progression to destructive insulitis suggests a dynamic 
involvement of different cell infiltrates and epitopes. It is debatable that whether 
non-antigen-specific T cells can enter the islet, but it is entirely possible that T 
cells recognizing different β-cell-derived epitopes are primed and recruited into 
the islet at different disease stages. This process involves shedding of different 
autoantigens and/or modification of preexisting epitopes, the so called 
“neoantigens” (Marrack and Kappler, 2012). Some evidence suggested a post 
translational modification of self-antigens in other autoimmune diseases (Abadie 
et al., 2011; Vossenaar et al., 2003), but in the context of T1D, an elegant study 
pointed out that unique binding of distinct peptide registers to I-Ag7 may be of a 
more prominent role in triggering diabetogenic responses (Mohan et al., 2011).  
It is conceivable that a breakdown of tolerogenic mechanisms is one important 
factor driving progressive insulitic lesions.  In fact , a number of studies have 
suggested that the loss of Treg function is a critical mediator in the disease 
progression (Bettini and Vignali, 2009), and this is associated with lack of IL-2 or 
defects in IL-2R signaling (Long et al., 2010; Tang et al., 2008). Furthermore, the 
decreased level of IL-2 and defective Treg function were associated with IL-2 
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single nucleotide polymorphism (SNP) within the Idd3 susceptibility locus in NOD 
mice (Yamanouchi et al., 2007). In addition, Tregs may be instable under 
inflammatory conditions (lose FoxP3 expression), and acquire a pathogenic 
phenotype (Zhou et al., 2009). However, these studies were challenged by other 
findings indicating that Tregs in the islets of NOD mice are able to suppress 
pathogenic T cells. For example, Tregs isolated from islet infiltrates were actively 
involved in modulation of diabetogenic T cell responses, but failed to regulate 
initial T cell recruitment to the islets (Chen et al., 2005). Another study used a 
conditional depletion mouse model for FoxP3+ Tregs, in which diphtheria toxin 
(DT) receptor is driven by the FoxP3 promoter (FoxP3.DTR) and injection of DT 
permits selective killing of FoxP3+ cells. The depletion of Tregs in NOD.BDC2.5 
TCR transgenic mice resulted in diabetes occurrence in all the mice within 40 
days (Feuerer et al., 2009). Furthermore, another study using an inducible fate-
mapping system to monitor Treg plasticity supported a notable stability rather 
than conversion of the committed FoxP3+ Tregs (Rubtsov et al., 2010). Therefore, 
Tregs in NOD mice appear to be able to contain pathogenic responses, but may 
not be sufficient at certain disease stages or in particular cellular 
microenvironments. Dissecting this paradox would require temporal and spatial 
Treg depletion experiments. Another important implication is that the essence of 
autoimmunity in T1D largely lies in the initiation and augmentation of pathogenic 
T cell responses, which is critically mediated by interaction between escaped 
thymic autoimmune emigrants with peptide-I-Ag7 complex, rather than intrinsic 
defects in central and peripheral tolerance mechanisms.  
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D. Concluding remarks 
Treating autoimmune diabetes is of great importance, but predicting or 
preventing the disease may be even more crucial for understanding and 
overcoming T1D autoimmunity. The initiation of the disease involves intriguing 
aspects as to the timing and the site for the beginning of T cell priming and the 
earliest changes in the islet of Langerhans. A recent study suggested that every 
NOD female mouse develops a signature of IFN-I in the islets at 4-week old of 
age, which precedes detectable activation of T cells (Carrero et al., 2013). This 
finding provides an essential starting point and a future framework for dissecting 
the initial immune events during T1D pathogenesis, especially since the 
presence of IFN-I is not related to viral infection or genetic predisposition and is 
unique to NOD mice (Carrero et al., 2013). On the other hand, the progression to 
destructive insulitis is another checkpoint for preventing the disease before 
critical loss of β-cell mass. This stage involves a complex network of interactions 
between pathogenic and regulatory elements. Despite the fact that the intrinsic 
defensive mechanisms in NOD mice may be defective in certain aspects, 
emerging evidence rather suggests a functional negative selection machinery 
and Treg function in NOD mice (Mingueneau et al., 2012). These studies 
highlighted the importance of the findings focused on analyses of the formation of 
the diabetogenic T cell responses based on the peptide-I-Ag7 complex (Calderon 
and Unanue, 2012; Mohan and Unanue, 2012; Mohan and Unanue, 2013). 
Indeed, a more favorable explanation (Figure 1) of T1D autoimmunity in NOD 
mice is that a group of the type B T cells, which only recognizes free peptides but 
not those from processing of the protein antigen, are not selected in the thymus 
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and are able to respond to a low concentration of the peptide antigens in the 
islets (Mohan et al., 2010; Mohan et al., 2011; Mohan and Unanue, 2012). 
Further scrutinization of these unique T cells would be the key to comprehend 
the T cell-driven events during initiation and propagation of autoimmune diabetes. 
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Adapted from Mohan et al., 2012 
Figure 1. A leading hypothesis of the formation of T1D autoimmunity. The 
deletion of autoreactive T cells in the medullary cortex is mediated by medullary 
thymic epithelial cells (mTECs). mTECs express a variety of tissue-specific 
antigens and endogenously process peptides derived from these antigens and 
present them to developing T cells. This process is highly effective in the deletion 
of conventional self-reactive T cell. However, owing to the constraints of 
processing protein antigens and the relatively low abundance of any given 
antigen, self-reactive T cells that show ‘type B’ peptide specificities may routinely 
escape negative selection. These type B T cells have the potential to be 
activated by APCs in the periphery, and this may result in autoimmune T cell 
responses. AIRE, autoimmune regulator.  
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3. ANTIGEN-SPECIFIC TREATMENT IN TYPE 1 DIABETES 
Immunotherapies aiming at re-establishing self-tolerance to insulin-producing β 
cells have been extensively studied. The majority of these therapies are 
designed to deplete and/or inactivate pathogenic T cells with or without 
activation/expansion of the regulatory T cells (Atkinson and Eisenbarth, 2001; 
Bluestone et al., 2010; Luo et al., 2010). In general, T-cell targeting therapies can 
be categorized into broad-based and antigen-specific strategies. The broad-
based therapies, especially the anti-CD3 monoclonal antibodies have shown 
efficacy in normalization of hyperglycemia in NOD mice and in preservation of C-
peptide responses in human patients (Chatenoud and Bluestone, 2007; 
Chatenoud et al., 1997; Chatenoud et al., 1994; Herold et al., 2005; Herold et al., 
2002; Keymeulen et al., 2005). However, these therapies are associated with 
safety issues by potentially compromising the normal function of the immune 
system against pathogen infections. In this regard, antigen-specific therapies that 
particularly target β-cell antigen-reactive T cells are more desired (Luo et al., 
2010). Due to the fact that different antigens, timing, routes and disease models 
are employed, varied effects of the therapies are observed in animal T1D models 
and human patients. Herein, the recent findings of the antigen-specific treatment 
in T1D are summarized in this section. 
 
A. GAD treatment 
To date, the most studied autoantigens in T1D are insulin and glutamic acid 
decarboxylase (GAD). The mouse and human islets differentially express two 
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isoforms of GAD (Bu et al., 1992; Christgau et al., 1991; Erlander et al., 1991), 
with the former predominantly expressing GAD67 (67KD) (Faulkner-Jones et al., 
1993), while the latter only expressing GAD65 (65KD) (Karlsen et al., 1992). 
GAD-reactive T cells are detected in NOD mice (Elliott et al., 1994; Kaufman et 
al., 1993; Tisch et al., 1993) and human patients (Endl et al., 1997; Honeyman et 
al., 1993; Panina-Bordignon et al., 1995; Rudy et al., 1995). Prevention of GAD 
expression in the pancreatic islets by antisense GAD RNA blocked T1D onset in 
NOD mice (Yoon et al., 1999). These results suggested that GAD is a prevalent 
antigen in T1D and prompted the studies aiming at inducing tolerance of GAD-
specific T cells (Kaufman et al., 1993; Ramiya et al., 1997; Tisch et al., 1999). In 
fact, administration of GAD through different routes in NOD mice resulted in anti-
diabetogenic effects, and the protection is associated with a shift of Th1 to Th2 
response and elevated serum IgG1 levels (Carter et al., 2006; Ma et al., 1997; 
Tian et al., 1996). Furthermore, vaccination of alum-formulated GAD (GAD-alum) 
in recently diagnosed T1D patients significantly delayed the loss of the C-peptide 
response (Agardh et al., 2005; Ludvigsson et al., 2008). Isolated PBMCs from 
those given GAD-alum had an increased mRNA level of FoxP3 and TGFβ gene 
expression as well as IFNγ, TNFα, IL-6, IL-17, IL-5 and IL-13 cytokine secretion 
(Ludvigsson et al., 2008). Although the treatment did not change the insulin 
requirement, the effects of GAD-related therapies in regulation of the immune 
system and improvement of the metabolic control are of note. 
Efforts in inducing GAD-specific T cell tolerance have been further extended to 
study individual peptides derived from GAD. Individual administration of GAD65 
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peptides spanning aa 217–236 (p217), 247–265 (p247), 290–309 (p290) and 
524–543 (p524) emulsified in incomplete Freund’s adjuvant (IFA) effectively 
resulted in disease prevention in 4-week NOD mice, but only the combination of 
p217 and p290 inhibited insulitis and diabetes development in 12-week NOD 
mice (Carter et al., 2006). Furthermore, the disease protection was absent in IL-
4-deficient mice (Carter et al., 2006). These findings suggest that GAD specific 
epitopes differ in their ability to induce regulatory Th2 response and that 
induction of disease protection in advanced disease stages is more likely to be 
dependent on certain GAD epitopes. Tolerogenic effects of other GAD peptides-
based treatment involved the IFNγ/IL-10-producing type 1 regulatory (Tr1) cells 
as exemplified by the GAD 206-220 (p206) and 221-235 (p221) cells. Tetramer 
isolated p206 or p221 antigen-specific cells from immunized mice secreted IFNγ 
and IL-10 and failed to induce diabetes upon transfer to NOD.scid recipients 
(Chen et al., 2003). Furthermore, these cells were able to delay diabetes onset 
when co-transferred with diabetogenic spleen cells and the suppressive ability of 
the p206 or p221 cells is directly correlated with their IFNγ and/or IL-10 
production (Chen et al., 2003). The regulatory function of the p206 cells has been 
further examined using the p206 TCR transgenic mice (Kim et al., 2004). 
Consistent with the tetramer-isolated cells, the TCR transgenic p206 cells 
produced IFNγ and IL-10 and inhibited transfer of diabetes (Kim et al., 2004). 
Interestingly, the p206 TCR transgenic mice lack insulitis and diabetes 
development even after crossing with mice over-expressing human GAD65 in the 
pancreas (Kim et al., 2004). Therefore, the inhibitory nature of the p206 cells is 
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not due to low presence of GAD in NOD mouse and increase of the local antigen 
does not convert these cells into a pathogenic phenotype. Furthermore, 
unstimulated p206 cells were not able to suppress transfer of diabetes, indicating 
that in vivo stimulation could enhance the ability of the p206 cells to down-
modulate pathogenic responses. In fact, p206 cells isolated from mice 
immunized with IFA/p206 displayed higher proliferative index than those from 
IFA-immunized mice (Kim et al., 2004), suggesting that administration of p206 
peptide under an uninflammatory condition was able to stimulate the p206 cells 
in vivo and amplify their suppressive functions. Based on these findings, our 
laboratory has genetically incorporated the aa sequence of p206 into an Ig 
backbone and tested the resulting Ig-p206 (referred to as Ig-GAD2) against T1D 
in multiple disease stages (Jain et al., 2008). Notably, Ig-GAD2 was able to 
normalize blood glucose levels (BGL) in hyperglycemic mice (BGL = 160-250 
mg/dl), but failed to prevent disease onset in young NOD mice before occurrence 
of insulitis (Jain et al., 2008). This is possibly due to the late reactivity of the 
p206-specific T cells in NOD mice. Interestingly, the protective effect of Ig-GAD2 
is associated with reduced IL-17 producing cells in the pancreas and periphery 
(Jain et al., 2008). These findings bode well with another study showing that 
administration of anti-IL-17 neutralizing antibodies in 10-wk old NOD mice 
suppressed insulitis and diabetes despite the fact that the role of Th17 cells in 
T1D remains obscure and debatable (Emamaullee et al., 2009).  
Different routes for administration of GAD peptides have been evaluated, among 
which the nasal or oral delivery shows values in practice and efficacy. Nasal or 
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oral administration of GAD 524-543 followed by injection of CFA in the footpad 
induced T cells producing IL-4, IL-10 and TGF and delayed diabetes transfer 
(Maron et al., 1999). Furthermore, intranasal delivery of GAD 247–266, GAD 
509–527, and GAD 524–543 delayed islet graft rejection possibly through 
enhanced IL-10 production (Ravanan et al., 2007).  
The safety of Alum-GAD has been tested in patients in a preclinical trial that 
showed non-detectable adverse effects in patients after injection with GAD with 
or without adjuvants (Plesner et al., 1998; Uibo and Lernmark, 2008). 
Subsequently, a phase II trial demonstrated that a 20 µg dose of alum-GAD was 
able to preserve C-peptide responses over a 24-week monitoring period 
accompanied by a increased CD4+CD25+/CD4+CD25- ratio (Agardh et al., 2005). 
Although the role of Tregs in the regulation of the pathogenic responses has 
been further supported by the increased FoxP3 and TGFβ gene expression in 
the PMBCs of patients 30 weeks after the first alum-GAD treatment, these 
patients also had increased levels of GAD autoantibody as well as expression of 
both proinflammatory and inhibitory cytokines (Ma et al., 1997). It is not 
surprising that GAD treatment displays a multifactorial regulation of the immune 
system; however, this adds difficulty to further distinction of the “beneficial” or 
“detrimental” responses. Indeed, frustrating results exist in that GAD treatment 
has not meet the primary expectation for reduction of insulin reliance in patients 
or reversal of T1D in NOD mice. Therefore, essential preclinical work is required 
for evaluating the choice of specific peptide treatment, the route of administration, 
antigen formulation, dosing and other factors. 
27 
 
B. Insulin treatment 
Despite the fact that insulin is the most prominent autoantigen in T1D 
pathogenesis, the insulin-specific treatments are somewhat less effective than 
GAD treatments especially in human patients. As the major hormone regulator of 
glucose homeostasis produced by pancreatic β-cells, insulin is the first 
autoantigen described in human patients (Palmer et al., 1983). Autoantibodies 
specific for both insulin and its precursor preproinsulin can be detected in 
patients with a recent onset of T1D (Kuglin et al., 1988; Yu et al., 2000). In 8-
week old NOD mice, presence of insulin autoantibody is associated with high 
disease incidence (Yu et al., 2000). Most insulin reactive CD4+ T cells in NOD 
mice recognize the segment of the insulin B chain composed of residues 9-23. 
Existing and emerging evidence suggests that insulin-reactive T cells may be the 
major initiator of the islet infiltration given that local islet antigen presenting cells 
are physiologically heavily loaded with B:9-23 peptide regardless of β-cell death 
and inflammation (Lieberman and DiLorenzo, 2003; Mohan et al., 2010; 
Nakayama et al., 2005). 
Therefore, targeting insulin-reactive T cells has been extensively studied in order 
to determine the proper routes or dosing for preventing or curing T1D. To date, 
oral, nasal, parenteral and intravenous routes have shown efficacy in preventing 
the disease in NOD mice (Aspord and Thivolet, 2002; Atkinson et al., 1990; 
Harrison et al., 1996; Hutchings and Cooke, 1995; Sai et al., 1996; Zhang et al., 
1991). It also has been shown that adjuvants such as cholera toxin could 
enhance the effectiveness of insulin treatment (Aspord and Thivolet, 2002; 
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Bergerot et al., 1997; Harrison et al., 1996). Interestingly, there is a B chain 
dependence of the insulin treatment because immunizing NOD mice with insulin 
B chain in IFA but not the A chain protected against T1D (Coon et al., 1999; Muir 
et al., 1995). Therefore, selection of the insulin epitope together with timing and 
routes of administration has been the major focus of insulin vaccination therapies, 
and different combination of these factors generated both disease protective and 
promoting results (Chen et al., 2001; Hutchings and Cooke, 1995). For example, 
subcutaneous delivery of proinsulin B24-C33 at 18 days of age promoted 
diabetes in NOD mice, while the intranasal route delayed onset of T1D (Chen et 
al., 2001). Therefore, the intranasal route appears to favor a tolerogenic 
response. This is further supported by other studies using proinsulin B24-C33, 
B24-C32, and insulin B: 9-23 peptide, which all displayed inhibition of 
diabetogenic responses (Daniel and Wegmann, 1996a; Daniel and Wegmann, 
1996b; Martinez et al., 2003). Interestingly, expansion of a group of antigen-
specific CD4+FoxP3+ regulatory T cells producing IL-10 and TGFβ was observed 
when intranasal delivery of proinsulin B24-C33 was synergized with anti-CD3 
monoclonal antibody treatment (Bresson et al., 2006). In contrast, the 
subcutaneous route generated mixed results as to disease protection or 
promotion. Immunizing 4-week old NOD mice with insulin-1 B: 9-23 peptide 
accelerated disease development, but immunization with insulin-2 B: 9-23 
peptide conferred disease protection (Devendra et al., 2004). Thus, the selection 
of appropriate peptide segments appears to be an important issue for design of 
insulin therapies. In addition, the effectiveness of the treatment is also disease 
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stage dependent. For example, immunization of prediabetic NOD mice with 
insulin B 9-23 with IFA was able to delay diabetes onset but failed to reverse 
established hyperglycemia (Daniel and Wegmann, 1996a; Fousteri et al., 2010; 
Hutchings and Cooke, 1995; Muir et al., 1995). This is perhaps because insulin is 
one of the earliest autoantigen present in the islet or pancreatic lymph node that 
may prime the first wave of T cell attack. Similar with GAD therapies, insulin-
related treatment is also associated with expansion of CD4+CD25+ Tregs and 
production of the immunoregulatory cytokines, such as IFNγ and IL-10 (Fousteri 
et al., 2010). 
To date, insulin treatment in human context has yielded disappointing results. 
Although insulin therapies did not cause detectable adverse effects and indeed 
downregulated insulin-specific T cell responses, they failed to prevent disease 
onset or delay β-cell damage (Harrison et al., 2004). Importantly, it seems that 
this is not due to the choice of dosing or routes of administration because 
different combination of these factors had similar results (Chaillous et al., 2000; 
Fourlanos et al., 2011; Nanto-Salonen et al., 2008; Orban et al., 2010; Pozzilli et 
al., 2000; Skyler et al., 2008; Skyler et al., 2005). Again, because little is known 
about the activity of insulin-reactive T cells in humans, one would envision that 
improvement of insulin treatment should largely rely on a more profound 
understanding of the insulin T cell autoreactivity. 
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C. Concluding remarks 
To summarize, both GAD and insulin therapies have shown their effectiveness in 
modulating the immune system, which may lead to disease prevention or 
protection. However, it should be noted that although β-cell loss and the eventual 
hyperglycemia are initiated by the immune attacks in the islet, reversal of such 
processes requires approaches beyond control of inflammation. Specifically, 
strategies facilitating restoration of insulin production of β-cells and/or recovery of 
the actual β-cell mass may be needed and combined with anti-inflammation 
therapies. Above all, the lack of success of the antigen-specific treatment in 
clinical trials suggests an urgent need for a clearer understanding of the initial 
and progressive immune events leading to β-cell failure. In this sense, 
humanized NOD mice may be of great value (Brehm et al., 2012). These efforts 
together with continuous optimization of the dosing and routes should eventually 
provide satisfactory translation of animal work to human T1D subjects.  
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ABSTRACT 
Autoimmune or type 1 diabetes (T1D) involves both Th1 and Th17 pathogenic 
cells. While the mechanisms underlying the control of Th1 cells are relatively 
well-defined, those operating modulation of Th17 cells remain largely unknown. 
Moreover, given that Th17 cells are plastic and can drive disease as stable or 
convertible T cells, effective approaches to counter T1D would have to alter Th17 
function under both circumstances. Herein, diabetogenic BDC2.5 Th17 cells 
were transferred into NOD mice under convertible or stable conditions and their 
fate was evaluated upon induction of tolerance and disease suppression. The 
findings show that upon induction of antigen-specific tolerance, convertible (Th17 
to Th1) cells display down-regulation of the chemokine receptor CXCR3 that was 
associated with diminished T-bet expression, retention of the cells in the spleen 
and inhibition of trafficking to the pancreas. In contrast, stable Th17 cells 
downregulated RORγt but increased FasL expression and died by apoptosis 
under the same antigen-specific tolerance.  Thus, the final signature transcription 
factor shapes the mechanism of tolerance in plastic Th17 cells. These findings 
suggest that effective strategies against T1D will require regimens that could 
drive both mechanisms of tolerance to overcome the disease. 
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INTRODUCTION 
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by T cell-
mediated destruction of pancreatic insulin-producing β cells. Studies of the 
nonobese diabetic (NOD) mouse model have revealed that Th1 cells are the key 
mediators of T1D (Katz et al., 1995; Wang et al., 1997). NOD mice lacking 
several Th1-associated regulators, including STAT4 (Yang et al., 2004) and T-
bet (Esensten et al., 2009), were prevented from the spontaneous disease onset; 
however, genetic deletion of IFNγ (Hultgren et al., 1996), IFNγ receptor (Serreze 
et al., 2000) or IL-12 (Trembleau et al., 1999) had little impact on disease 
development in NOD mice. These discrepancies indicate a potential role of other 
effector CD4 T cell subsets during the development of T1D. 
More recently, Th17 cells have been demonstrated to be involved in T1D 
pathogenesis. Elevated IL-17 expression was detected in diabetic NOD mice 
(Martin-Orozco et al., 2009), and IL-17 neutralization inhibited disease 
progression from the effector phase (Emamaullee et al., 2009). A previous study 
from our laboratory has demonstrated that treatment of hyperglycemic mice with 
a chimeric agent consisting of immunoglobulin (Ig) and GAD65 peptide 206-220 
restored normoglycemia through inhibition of IL-17 response in spleen and 
pancreas (Jain et al., 2008). In human patients, monocytes isolated from TID 
individuals secreted IL-6 and IL-1, which induced and expanded Th17 cells 
(Bradshaw et al., 2009). Enhanced IL-17, RORC2 and IL-22 expression upon 
monocyte activation was associated with recently diagnosed T1D in children 
(Honkanen et al., 2010). These findings suggest that Th17 cells are mediators 
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and potential therapeutic targets in T1D. However, mechanisms underlying 
tolerance of diabetogenic Th17 cells remain largely unknown. 
Differentiation of naive CD4 T cells to the Th17 lineage is programmed by IL-6, 
TGF-β and IL-1β (Bettelli et al., 2006; Mangan et al., 2006; Sutton et al., 2006; 
Veldhoen et al., 2006), and IL-23 is required for maintenance and expansion of 
differentiated Th17 cells (Ahern et al., 2010; McGeachy et al., 2009). However, 
instructed by different cytokine milieus, Th17 development can be directed to 
other effector programs (Zhou et al., 2009). In particular, increased 
concentrations of IL-12 and TGF-β can shift Th17 differentiation to either Th1 or 
Treg pathway, respectively, giving rise to the notion of “Th17 plasticity” (Lee et 
al., 2009; Zhou et al., 2008). In autoimmune settings, plastic Th17 cells are able 
to switch their pathogenic phenotypes in response to variable environmental 
cues, resulting in robust autoimmune responses. Specifically, highly 
differentiated Th17 cells need to convert into a Th1-like profile before efficiently 
inducing T1D in lymphopenic environments (Bending et al., 2009; Martin-Orozco 
et al., 2009). On the other hand, polarized Th17 cells stayed stable when 
transferred into WT hosts (Nurieva et al., 2009), and may drive T1D development 
through recruiting macrophages to the islets (Martin-Orozco et al., 2009). These 
findings indicate that Th17 cells exert differential pathogenic functions due to 
their plasticity shaped by various environmental factors. Therefore, 
comprehensive understanding of Th17 tolerance would require analyses based 
on both cell converting and non-converting settings. 
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In the present study, we attempted to explore the mechanisms underlying 
tolerance of plastic Th17 cells using the well-established adoptive transfer model 
of BDC2.5 T cells into NOD.scid or NOD recipients. Furthermore, we devised an 
effective tolerogenic Immunoglobulin (Ig)-based treatment by expressing the 
library defined BDC2.5-reactive p79 peptide (Judkowski et al., 2001; You et al., 
2003) on the Ig backbone. The resulting Ig-p79 was then used in the transfer 
model of T1D to investigate tolerance of Th17 cells. The results show that Th17 
cells transferred into NOD.scid mice converted into Th1 cells and the treatment 
with Ig-p79 suppressed diabetes by interfering with the expression of the 
chemokine receptor CXCR3 on the converted Th1 cells, leading to retention of 
these cells in the spleen and impaired trafficking to the target pancreas. In 
contrast, when the Th17 cells were transferred into NOD mice, they were unable 
to convert to Th1 cells and underwent apoptosis upon treatment with Ig-p79. 
Finally, the different fates of Th1 and Th17 cells were tied to their signature 
transcription factors as down-regulation of T-bet led to diminished expression of 
CXCR3 and modulation of RORγt led to increased FasL expression. These 
previously unrecognized tolerogenic mechanisms should contribute to the 
development of effective therapeutic strategies against diabetes.             
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RESEARCH DESIGN AND METHODS 
 
Mice  
NOD (H-2g7), NOD.scid, NOD.BDC2.5, BALB/c.IL-12atm1Jm (IL-12p35−/−) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME). 
NOD.FoxP3GFP.DTR mice were generated by breeding C57BL/6.FoxP3.GFP.DTR 
mice onto the NOD background for 7 backcross generations. The 
NOD.FoxP3GFP.DTR mice were then bred with NOD.BDC2.5 mice to generate 
NOD.BDC2.5.FoxP3GFP.DTR mice. NOD.scid.IL-12p35−/− mice were generated by 
breeding BALB/c.IL-12p35−/− mice with NOD.scid mice for 7 backcross 
generations. All mice were used according to the guidelines of the University of 
Missouri Animal Care and Use Committee. 
 
Peptides and Ig chimeras 
All peptides used in this study were purchased from Metabion and purified by 
HPLC to >95% purity. p79 peptide corresponds to the library defined mimotope 
(AVRPLWVRME) reactive with BDC2.5 diabetogenic T cells (Judkowski et al., 
2001; You et al., 2003). Hen egg lysozyme (HEL) peptide corresponds to aa 
residues 11-25 (AMKRHGLDNYRGYSL) of HEL. Ig-p79 and Ig-HEL express p79 
and HEL peptide, respectively. The genetic engineering of p79 peptide into the 
heavy chain of the 91A3 anti-arsonate antibody and the production of Ig-p79 was 
accomplished according to methods used to generate Ig-HEL (Gregg et al., 
2004). 
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T cell polarization 
Splenic cells (2 x 106/ml) from 4-6-wk naïve NOD.BDC2.5.FoxP3GFP.DTR mice 
were depleted of red blood cells and stimulated with p79 peptide (0.5µM) under 
Th1 or Th17 conditions for 4 days. For polarization into Th1 cells, the stimulation 
was carried out in the presence of rIL-12 (10ng/ml, peprotech) and anti-IL-4 
(10µg/ml, 11B11). For Th17 polarizaton, the culture was supplemented with 
rTGF-β (3ng/ml, peprotech), rIL-6 (20ng/ml, peprotech), anti-IFNγ (10µg/ml, R4-
6A4) and anti-IL-4 (10µg/ml, 11B11) antibodies.  rIL-23 (20ng/ml, R&D Systems) 
was added to the culture for the last 2 days.  
 
Retroviral transduction 
The MSCV-CXCR3-IRES-Thy1.1 and empty MSCV-IRES-Thy1.1 vector used to 
over-express CXCR3 in polarized Th17 cells were previously described (Hu et 
al., 2011). Briefly, 293FT cells (Invitrogen) were transfected with either MSCV-
CXCR3-IRES-Thy1.1 or MSCV-IRES-Thy1.1 vector along with the retroviral 
packaging vector (pψECO) by calcium chloride. The culture supernatant 
containing the retroviruses was used to transduce Thy1.2 BDC2.5 T cells during 
polarization to Th17 cells. Briefly, the naïve T cells were cultured under polarizing 
conditions and the viral supernatant was added 24h later. The culture was then 
spun down (2500rpm for 1h at 23°C), the supernatant was discarded and the 
pelleted infected cells were resuspended in fresh polarizing media and the 
culture was continued for 3 days. The CD4+ T cells were then isolated and used 
for transfer experiments. 
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Purification and adoptive transfer of polarized Th1 and Th17 cells 
CD4+ T cells were isolated from the culture by negative selection using CD4 T 
cell isolation kit II from Miltenyi Biotec. The CD4+ T cells (2 x 106/ml) were then 
stimulated with PMA (50ng/ml) and ionomycin (500ng/ml) for 2h and the cells 
were labeled using the Mouse IFNγ (APC) and IL-17 (PE) detection kit from 
Miltenyi Biotec. Subsequently, the enriched Th17 (IL-17+IFNγ−FoxP3−) and Th1 
(IFNγ+IL-17−FoxP3−) cells were sorted to at least 98% purity using a Beckman 
Coulter MoFlo XDP sorter. 
For adoptive transfer, 3x106 purified cells were transferred i.v. into NOD.scid 
mice, and 1x107 cells were transferred i.v. into NOD or NOD.FoxP3GFP.DTR mice. 
 
Treatment with Ig-p79 chimera and neutralizing anti-cytokine antibodies 
Ig-p79 and the control Ig-HEL were injected into mice (300 µg/ mouse) i.p. a few 
hours after transfer of T cells. For in vivo neutralization of IFNγ or IL-17, the mice 
were given anti-IFNγ (R4-6A4), anti-IL-17(TC11-18H10), and isotype Rat IgG1 
control (300 µg per injection) i.p. on day 0, 2, 4 and 6 after cell transfer.  
 
Depletion of Tregs 
Diphtheria toxin (Sigma) was given to NOD.FoxP3GFP.DTR mice i.p. (300 
ng/mouse/injection) on days -2, -1, 2, 5, 8, 11 and 14 after cell transfer.  
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Antibodies 
Anti-CD4 (RM4-5), anti-Vβ4 (KT4), anti-IFNγ (XMG1.2) and anti-IL-17 (TC11-
18H10) were purchased from BD Pharmingen. Anti-T-bet (ebio4B10) and anti-
RORγt (AFKJS-9) were purchased from eBioscience. Anti-CXCR3 (CXCR3-173), 
anti-CCR6 (29-2L17), and anti-FASL (MFL3) were purchased from Biolegend. 7-
amino-actinomycin D (7-AAD) was purchased from EMD Biosciences. 
 
Intracellular staining 
For detection of intracellular IFNγ and IL-17 in CD4+ T cells from NOD.scid mice, 
the cells were stimulated with PMA (50ng/ml) and ionomycin (500ng/ml) for 2h in 
presence of Brefeldin A (10µg/ml). For detection of intracellular IFNγ and IL-17 in 
T cells  from NOD or NOD.FoxP3GFP.DTR mice, total splenic cells were stimulated 
with p79 mimotope (0.5µM) for 16h with addition of  Brefeldin A (10µg/ml) for the 
last 2h. For flow cytometry analyses, the cells were then stained for surface 
markers, fixed in 2% formaldehyde, permeabilized with 0.2% saponin and 
stained for intracellular cytokines. 
For nuclear detection of T-bet and RORγt, the cells were stained for surface 
markers, treated with the Fix/Perm buffer (eBioscience) and then stained with 
anti-T-bet and anti-RORγt according to the manufacturer’s instructions. 
Flow cytometry analyses were read using a Beckman Coulter CyAn ADP and 
data were analyzed using Summit V4.3 (Dako). 
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Isolation of pancreatic cells 
Pancreatic islets and infiltrating cells were purified as described (Faveeuw et al., 
1995). Briefly, the pancreata were digested with collagenase Type IV (Invitrogen) 
and islets were separated on a ficoll gradient (GE Healthcare). The morphology 
of purified islets was confirmed by light microscopy, and the infiltrating cells were 
isolated by mechanical disruption.  
 
Histology 
Pancreata were frozen in OCT compound at −80°C. Cryosections of 8µm 
thickness were cut 200µm apart to prevent double counting of the same islet. At 
least three non-serial sections per pancreas were stained with hematoxylin and 
eosin and analyzed by light microscopy. Insulitis scoring was performed 
according to the following criteria: Intra-insulitis, severe infiltration within the islet;  
peri-insulitis, infiltration is restricted to the periphery of islets; and no insulitis, 
absence of cell infiltration. 
 
Quantitative PCR analysis 
The total RNA of pancreatic islets was extracted using the TRI RNA isolation 
reagent (Sigma). Quantitative PCR was performed using the Power SYBR Green 
kit and the StepOnePlus instrument (all from Applied Biosystems). The primers 
are as follows: ccl9, forward, 5’-CGAGGCACGATCCACTACAAAT-3’; reverse, 
5’-TCTAGGCAGGTTTGATCTCCGT-3’. ccl10, forward, 5’-CATCAGCACCA 
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TGAACCCAAGT-3’; reverse, 5’-TTCCCTATGGCCCTCATTCTCA-3’. ccl11, 
forward, 5’-AATTTACCCGAGTAACGGCTGC-3’; reverse, 5’-
ATTATGAGGCGAGC 
TTGCTTGG-3’. ccl20, forward, 5’-CTGCTCTTCCTTGCTTTGGCAT-3’; reverse, 
5’-CATCGGCCATCTGTCTTGTGA-3’. Actb, forward, 5’-
TACAATGAGCTGCGTGTGG 
C-3’; reverse, 5’-AGCCTGGATGGCTACGTACA-3’. Gene expression was 
calculated based on ΔΔCT upon normalization to Actb gene expression. 
 
Statistics 
The p values were calculated using the two-tailed Student t test. 
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RESULTS 
Environmental IL-12 is essential for Th17 cells to convert into Th1 cells and 
efficiently induce T1D in NOD.scid mice. 
To ensure the purity of the transferred Th1 or Th17 cells, we selectively enriched 
and sorted the IFNγ+IL-17− or the IL-17+IFNγ− fraction from Th1 or Th17 
polarizing cultures, respectively. The purities obtained were routinely higher than 
98% (Fig. 1).  
 
 
 
Figure 1. Sorted Th1 and Th17 cells display high degree of purity. Splenic 
cells from NOD.BDC2.5.FoxP3GFP.DTR mice were cultured under Th1 and Th17 
polarizing conditions and the CD4+ T cells were isolated by negative selection. 
The purified T cells were then stimulated with PMA/ionomycin for 2h, and IFNγ- 
(Th1) and IL-17- (Th17) producing T cells were labeled using the Mouse IFNγ 
and IL-17 detection kit. The culture was depleted of GFP+ (Tregs) cells and the 
Th1 and Th17 cells were sorted using the MoFlo XDP sorter. The panels show 
polarized Th1 and Th17 cells before and after sorting.  
 
57 
 
These highly purified Th1 or Th17 cells were then transferred into NOD.scid 
recipients, and the mice that received Th17 cells developed diabetes on day 8 or 
9 post transfer, while transfer of Th1 cells induced diabetes on day 4 or 5 (Fig. 
2A). Despite the thorough depletion of IFNγ+ contaminants from Th17 cells 
before transfer (Fig. 1, right panels), a sizable portion of IFNγ-producing cells 
(7.1%) was readily detectable in pancreatic lymph nodes (PLN) on day 3 post 
transfer, whereas 23% of the transferred Th17 cells still maintained the IL-17 
production (Fig. 2B, left panel). However, the IFNγ-producing cells outnumbered 
the IL-17-producers by day 7 post transfer (Fig. 2B, right panel), suggesting that 
Th17 cells have actively converted into a Th1 profile before disease induction. 
Furthermore, in vivo neutralization of IFNγ completely abrogated Th17-initiated 
diabetes induction, whereas mice treated with anti-IL-17 still developed normal 
disease (Fig. 2C), suggesting that conversion into Th1 cells is necessary for 
Th17 cells to acquire the full competence to effectively induce diabetes.  
We next attempted to examine the key factor responsible for the in vivo Th17 to 
Th1 conversion. Previous studies have demonstrated that Th17 cells express the 
IL-12 receptor and in vitro exposure to IL-12 substantially upregulated IFNγ and 
T-bet expression in Th17 cells (Bending et al., 2009; Lee et al., 2009). Therefore, 
we utilized the IL-12(p35)−/−.NOD.scid mice as hosts, and analyzed whether the 
absence of environmental IL-12 would affect the Th17 to Th1 conversion in vivo. 
Indeed, kinetic cytokine analyses revealed a consistent lower frequency of IFNγ-
producing but a higher frequency of IL-17-producing cells in spleen and pancreas 
in IL-12(p35)−/− mice as compared to the IL-12(p35)+/+ counterparts (Fig. 2D). The 
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ratio of IFNγ- to IL-17-producing cells in spleen and pancreas was significantly 
higher in IL-12(p35)+/+ mice relative to the IL-12(p35)−/− mice on day 4, 8 and 14 
post transfer (Fig. 2E). Furthermore, only 20% of the IL-12(p35)−/−.NOD.scid mice 
developed diabetes following Th17 transfer, whereas all the IL-12(p35)+/+ 
littermates developed robust disease (Fig. 2F, left panel). On the other hand, 
transfer of Th1 cells induced a similar kinetics of disease development in both IL-
12(p35)−/− and IL-12(p35)+/+ recipients (Fig. 2F, right panel). Collectively, these 
results demonstrate that IL-12 in the lymphopenic environment is essential for 
Th17 cells to convert into Th1 cells and induce potent diabetes. 
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Figure 2: Th17 cells undergo cell conversion to sustain development of 
T1D in NOD.scid mice.  (A) BDC2.5 T cells were polarized into Th1 or Th17 
cells, transferred into NOD.scid mice and the hosts (n = 15 and 16 per group, 
respectively) were monitored for incidence of diabetes.   (B) Kinetics of Th17 to 
Th1 conversion as measured by intracellular staining of IFNγ and IL-17 in PLN 
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CD4+Vβ4+ T cells on day 3, 5 and 7 following cell transfer. Numbers indicate the 
percentage of cells in each quadrant. (C) Neutralization of cytokines in vivo by 
treatment of Th17-recipient NOD.scid mice with anti-IL-17 (n = 8), anti-IFNγ (n = 
6), or Rat IgG1 isotype control (n = 8). (D-F) Polarized BDC2.5 Th17 or Th1 cells 
were transferred into IL-12(p35)-/- or IL-12(p35)+/+ NOD.scid mice and the  hosts 
were monitored for blood glucose levels.  (D) shows kinetics of cell  conversion 
measured by intracellular cytokine staining of splenic and pancreatic  CD4+Vβ4+ 
T cells on day 4, 8, and 14 following cell transfer. Numbers indicate the 
percentage of cells in each quadrant. (E) shows the ratio of Th1 to Th17 (% 
IFNγ-producing cells over % IL-17-producing cells) compiled from 3 independent 
experiments. Each bar represents mean ± SEM of 6 mice. (F) shows incidence of 
diabetes (n = 12).  ** P < 0.01, * P < 0.05. The experiments were performed twice 
(C) or three times (A, B, D, F) with consistent results.  
 
Tolerance of the converted Th1 cells accounts for suppression of T1D 
induced by Th17 cell transfer. 
To explore the mechanisms underlying the tolerance of Th17 cells in the 
converting environment, we started by injecting tolerogens to NOD.scid mice 
along with Th17 transfer. To magnify tolerance, the 1140-79 mimotope (p79), 
which displayed a high affinity to BDC2.5 T cells (Judkowski et al., 2001), was 
genetically incorporated into an Ig molecule. The resulting Ig-p79 was used to 
test against T1D. Similarly, the nondiabetogenic I-Ag7-restricted hen egg 
lysozyme (HEL) 11-25 sequence was also incorporated into an Ig, and the 
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resulting Ig-HEL was used as a control treatment. As shown in Fig. 3A, 100% of 
the mice treated by Ig-p79 were protected against T1D following Th17 transfer, 
whereas mice treated by Ig-HEL and soluble p79 developed a rapid onset of 
T1D. Therefore, the protection mediated by Ig-p79 could be due to disturbed 
Th17 to Th1 conversion and/or inactivation of the converted Th1 cells. Indeed, 
IFNγ-producing cells can be detected in the spleen and pancreas on both day 4 
and 8 following Ig-p79 treatment, indicating a sustained level of Th17 to Th1 
conversion in Ig-p79-treated mice (Fig. 3B). Thus, it is unlikely that Ig-p79 
suppressed the disease through inhibition of the conversion.  
Because the disease is likely driven by the converted Th1 cells (Fig. 2C), we 
sought to determine the presence of these cells in the site of inflammation 
(pancreas) to correlate tolerance with the suppression of the disease. Indeed, the 
IFNγ+IL-17− (converted Th1) cells displayed a strikingly lower frequency (Fig. 3B, 
right panel) and absolute number (Fig. 3C, right panel) in the pancreas on both 
day 4 and 8 during treatment with Ig-p79 relative to Ig-HEL. In contrast, these 
cells accumulated more efficiently in the spleen by both criteria in mice given Ig-
p79 relative to Ig-HEL (Fig. 3B and C, left panels). These results indicate that the 
converted Th1 cells may have impaired abilities to migrate into pancreas and are 
therefore retained in the spleen. It should be noted that the number of the 
IFNγ−IL-17+ (unconverted Th17) cells remained minimal in the pancreas on both 
day 4 and 8 (Fig. 3C, right panel), indicating an inability of these cells to migrate 
into pancreas. Furthermore, the number of the unconverted Th17 cells was 
consistently comparable between Ig-p79 and Ig-HEL groups (Fig. 3C), 
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suggesting that tolerance induction did not involve these cells. Overall, these 
results suggest that although disease development occurs through conversion 
from Th17 to Th1 cells, its suppression is mediated by interference with 
trafficking of the converted Th1 cells. 
 
 
Figure 3. Treatment with Ig-p79 retained the Th17-derived Th1 cells in the 
spleen and impaired their trafficking into pancreas. (A) NOD.scid mice 
recipient of Th17 polarized BDC2.5 cells were treated with p79 peptide (n = 8), 
Ig-p79 (n = 14), or the control Ig-HEL (n = 16) and then monitored for blood 
glucose levels for a period of 16 days. (B-C) CD4+ T cells were isolated from the 
spleen and pancreatic islets of Ig-HEL and  Ig-p79-treated mice (n = 6 per group) 
on day 4 and 8 post Th17 cell transfer, stimulated in vitro with PMA/ionomycin for 
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2h in the presence of Brefeldin A, and intracellular IFNγ and IL-17 were 
measured in CD4+Vβ4+ T cells. (B) shows a representative dot plot cytokine 
measurement with the numbers in each quadrant indicating the percentage of 
cytokine positive cells. (C) shows the absolute number of IFNγ+IL-17−  or IFNγ−IL-
17+ cells in spleen (left panel) and pancreas (right panel). Each bar represents 
mean ± SEM of 12 mice from 4 experiments. ** P < 0.01 * P < 0.05. 
 
Treatment with Ig-p79 interferes with CXCR3 expression on converted Th1 
cells.  
To test the hypothesis that Ig-p79 may dampen the trafficking ability of the 
converted Th1 cells and cause ineffective infiltration of these cells into pancreas, 
we attempted to investigate whether Ig-p79 affected the expression of chemokine 
receptors on the converted Th1 cells. In line with previous findings (Singh et al., 
2008; Syrbe et al., 1999), polarized Th17 BDC2.5 cells expressed high levels of 
CCR6 (87%), the signature Th17-associated chemokine receptor, and low levels 
of CXCR3 (26%), which is usually highly expressed on Th1 cells (65%) (Fig. 4A). 
Interestingly, the CXCR3loCCR6hi Th17 cells upregulated CXCR3 (82%) and 
downregulated CCR6 (12%) expression upon converting into IFNγ+IL-17− Th1 
cells in Ig-HEL treated mice, whereas cells that were IFNγ−IL-17+ still maintained 
high CCR6 (89%) and low CXCR3 (33%) expression (Fig. 4B, upper panels). 
Thus, the Th17 to Th1 conversion is accompanied by the acquisition of the 
CXCR3 expression on the converted Th1 cells, which could be important for 
directing these cells into pancreas and induce β cell damage. On the other hand, 
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when treated by Ig-p79, only 42% of the converted Th1 cells expressed CXCR3 
(Fig. 4B, lower panels), indicating that the majority of these cells would be limited 
for migration into the site of inflammation. In addition, quantification of CXCR3 
MFI demonstrated that Ig-p79 treatment significantly downregulated CXCR3 
expression on converted Th1 cells in spleen and PLN (Fig. 4C). These results 
indicate that the CXCR3 interference took place in spleen and PLN when the 
transferred cells encounter Ig-p79, resulting in limited pancreatic infiltration of 
these cells. We also examined another Th1-associated chemokine receptor 
CCR5, which consistently remained at the background level on the converted 
Th1 cells regardless of treatment with Ig-p79 or Ig-HEL (data not shown). 
Furthermore, only 43% of the converted Th1 cells treated by Ig-p79 expressed T-
bet as compared to 85% of the cells treated by Ig-HEL (Fig. 4D). Given that 
CXCR3 transcription is controlled by binding of t-bet to the CXCR3 promoter 
region, (Beima et al., 2006; Koch et al., 2009), it is likely that Ig-p79 interfered 
with CXCR3 expression through inhibition of the upstream T-bet expression.  
Considering the migration of CXCR3-bearing T cells to the site of inflammation is 
directed by the chemotaxis towards the CXCR3 chemokine ligands, including 
CCL9, CCL10 and CCL11, we next examined if Ig-p79 would affect CXCR3 
ligands expression in the pancreatic islets. We first confirmed the enhanced 
CXCR3 ligands expression in pancreatic islets induced by Th17 cell transfer, 
which could be essential for recruiting CXCR3-expressing T cells. Specifically, a 
35-50-fold upregulation of CCL9 and CCL10 gene expression was detected on 
day 8 by Th17 transfer as compared to the no transfer group (Fig. 4E). The high 
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level of ccl9 and ccl10 expression was also maintained in the pancreas of mice 
given either Ig-HEL or Ig-p79 (Fig. 4E). Thus, pronounced expression of CXCR3 
ligands was established in the pancreatic islets of the Ig-p79-treated mice, 
suggesting that downregulation of CXCR3 rather than insufficient stimuli is the 
major contributor to the impaired trafficking of the converted Th1 cells. Notably, 
the CCR6 ligand CCL20, which displayed robust chemotaxis for CCR6+ Th17 
cells (Reboldi et al., 2009), remained at a basal level in all the experimental 
groups (Fig. 4E). Thus, despite the fact that the unconverted Th17 cells highly 
expressed CCR6 (Fig. 4B), the lack of CCL20 may account for the rare presence 
of these cells in pancreas (Fig. 3C). 
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Figure 4: Treatment with Ig-p79 interferes with CXCR3 expression on 
converted Th1 cells.  (A) shows expression of CXCR3 and CCR6 on polarized 
Th1 and Th17 cells. The results are representative of 4 independent 
experiments. (B-C) NOD.scid mice were transferred with Th17 polarized BDC2.5 
cells and treated with Ig-HEL or Ig-p79 (3-6 mice per group). The mice were 
sacrificed on day 8 after treatment and their splenic and PLN CD4+ T cells were 
isolated. The T cells were then stimulated with PMA/ionomycin for 2h in the 
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presence of Brefeldin A and stained for surface CXCR3 and CCR6 and for 
intracellular IFNγ and IL-17. (B) shows a representative experiment of splenic 
CD4+Vβ4+IFNγ+IL-17− (converted Th1) and IFNγ−IL-17+ (unconverted Th17) cells 
(left panels) and expression of CXCR3 and CCR6 by each population (right 
panels). (C) shows MFI of CXCR3 expression on splenic and PLN 
CD4+Vβ4+IFNγ+IL-17− cells on day 8 after treatment with Ig-p79 or Ig-HEL. Each 
bar represents the mean ± SEM of 10 mice from 3 independent experiments. (D) 
shows T-bet expression by splenic CD4+Vβ4+IFNγ+IL-17− cells on day 8 after Ig-
p79 or Ig-HEL treatment. The results are representative of 3 independent 
experiments. (E) Quantitative PCR analysis of cxcl9, cxcl10, cxcl11 and cxcl20 
chemokine expression in pancreatic islets on day 8 following Ig-p79 or Ig-HEL 
treatment. Each bar represents the mean ± SEM of 7 mice from 2 independent 
experiments. The numbers in histograms (A, B, D) represent the percentage of 
cells that are positive for expression for the indicated markers. ** P < 0.01. * P < 
0.05. 
 
In parallel, we analyzed in vivo proliferation and survival of the converted Th1 
cells, which could also contribute to the rare presence of these cells in pancreas 
of the Ig-p79-treated mice. However, the purified IFNγ+IL-17− cells from Ig-HEL 
or Ig-p79-treated mice displayed similar levels of CFSE dilution and 7-AAD 
incorporation (Fig. 5), suggesting that Ig-p79 treatment did not affect the 
proliferation and apoptosis rate of the converted Th1 cells in vivo. Therefore, 
these results further confirm that the minimal presence of converted Th1 cells in 
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the pancreas of the Ig-p79-treated mice is mainly due to their impaired trafficking 
abilities. 
 
 
 
Figure 5. Converted Th1 cells display equivalent proliferative and survival 
attributes in the spleen and pancreas of Ig-p79-versus Ig-HEL- treated 
NOD.scid mice. NOD.scid mice were transferred with CFSE-labeled Th17 cells, 
and the hosts were treated with Ig-p79 or the control Ig-HEL. The converted Th1 
cells were then sorted from the spleens and pancreata and analyzed for CFSE 
dilution (A) and incorporation of 7-AAD (B) as a measure of proliferation and 
survival, respectively.  The numbers represent MFI (A) and mean ± SEM percent 
of 7-AAD+ cells (B). The results are representative of 3 independent experiments.   
 
Downregulation of CXCR3 expression on regular Th1 cells after treatment 
with Ig-p79. 
Next we asked if the tolerance of converted Th1 cells can also be applied to 
polarized genuine Th1 cells. To this end, polarized Th1 cells were transferred 
into NOD.scid mice, and disease development in the recipients was monitored 
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during treatment with Ig-p79 or Ig-HEL. As shown in Fig. 6A, the Th1-mediated 
diabetes was prevented by Ig-p79, but not Ig-HEL or p79 peptide. Compared with 
the Ig-HEL-treated controls, IFNγ+ cells were present at a lower frequency in 
pancreas when treated with Ig-p79, while these cells had a higher frequency in 
the spleen (Fig. 6B). Correspondingly, the absolute cell number of the 
IFNγ+CD4+Vβ4+ cells in pancreas was significantly lower in Ig-p79-treated mice 
on day 5 as compared to the Ig-HEL-treated controls (Fig. 6C, right panel). 
However, these cells were present at a significantly higher number in the spleen 
(Fig. 6C, right panel). Thus, it is likely that Ig-p79 impaired the trafficking ability of 
the transferred Th1 cells and limited their migration to the pancreas. Indeed, the 
splenic Th1 cells from Ig-p79-treated mice had a significantly lower level of 
CXCR3 and T-bet expression than the Ig-HEL-treated controls (Fig. 6D and E). 
Furthermore, all the three CXCR3 chemokine ligands (CCL9, CCL10 and 
CCL11) were highly upregualted (10 to 75 folds) in the pancreatic islets after 
transfer of Th1 cells, and this upregulation was maintained during treatment with 
either Ig-p79 or Ig-HEL (Fig. 6F). These results suggest that the diminished 
CXCR3 expression on the Ig-p79-tolerized Th1 cells resulted in abrogated 
trafficking and pancreatic infiltration. Thus, both the converted and regular Th1 
cells use a similar mechanism upon tolerance. 
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Figure 6. Polarized, like converted Th1 cells, down-regulate CXCR3 upon 
treatment of the NOD.scid host with Ig-p79. (A) Polarized Th1 cells were 
transferred into NOD.scid mice and the hosts were treated with p79 peptide (n = 
8), Ig-HEL (n = 12), or Ig-p79 (n = 16) and monitored for blood glucose levels. 
The graph shows diabetes incidence during a 16-day monitoring period. (B) 
shows intracellular IFNγ and IL-17 production by splenic and pancreatic 
CD4+Vβ4+ T cells harvested on day 5 after Th1 transfer. The results are 
representative of 3 independent experiments. The numbers indicate the 
percentage of cells in each quadrant. (C) shows the absolute number of 
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IFNγ+CD4+Vβ4+ T cells in the spleen and pancreas on day 2 and 5 after Th1 
transfer. Each point represents the mean ± SEM of 10 mice from 3 independent 
experiments. (D) shows CXCR3 and T-bet expression on splenic IFNγ+CD4+Vβ4+ 
T cells on day 5 after Th1 transfer. The results are representative of 4 
independent experiments. (E) shows MFI of CXCR3 and T-bet on Th1 cells 
described in (D). Each bar represents the mean ± SEM of 12 mice. (F) 
Quantitative PCR analysis of cxcl9, cxcl10, cxcl11 and cxcl20 chemokine 
expression in pancreatic islets on day 5 after Th1 transfer. Each bar represents 
mean ± SEM of 6 mice from 2 independent experiments. ** P < 0.01. * P < 0.05. 
 
Overexpression of CXCR3 on Th17 cells nullifies tolerance. 
Tolerance of converted and polarized Th1 cells likely operates at the level of 
chemokine receptor expression and its consequent effect on trafficking.  In fact, 
when CXCR3 was over-expressed in the polarized Th17 cells, Ig-p79 was no 
longer able to suppress the disease despite conversion of the cells into Th1 cells 
(Fig. 7). Indeed, when polarized Thy1.2 BDC2.5 Th17 cells were infected with the 
mouse stem cell virus (MSCV) carrying CXCR3-IRES-Thy1.1 (Hu et al., 2011), 
93% of the cells that were transduced (expressing Thy1.1) had CXCR3 
expression (Fig. 7A). Furthermore, when the CXCR3-transduced Th17 cells were 
transferred into NOD.scid mice, the hosts developed a slightly faster onset of 
diabetes relative to the control mice recipient of empty vector-transduced cells 
(Fig. 7B). The cells did convert into Th1 cells whether transduced with CXCR3 or 
empty vector as 31% and 28% of the cells produced IFNγ, respectively (Fig. 7C). 
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Interestingly, while the mice recipient of Th17 cells transduced with empty vector 
did not develop T1D when treated with Ig-p79, those recipient of CXCR3-
transduced Th17 cells did (Fig. 7D). Treatment with Ig-HEL did not protect 
against the disease whether the cells were transduced with CXCR3 or empty 
vector. These observations indicate that over-expression of CXCR3 nullifies Ig-
p79-induced tolerance.  Overall, down-regulation of CXCR3 is essential for 
tolerance of Th1 cells and suppression of T1D.   
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Figure 7. Over-expression of CXCR3 in plastic Th17 cells confers 
resistance to converted Th1 cells against Ig-p79-induced tolerance. (A-C) 
Polarized Th17 BDC2.5 T cells (Thy 1.2) were transduced ex vivo with MSCV-
CXCR3-IRES-Thy1.1 or empty MSCV-IRES-Thy1.1 vector and transferred into 
NOD.scid mice. The hosts were then monitored for blood glucose levels and the 
transferred Th17 cells were analyzed for Th17 to Th1 conversion. (A) shows the 
expression of Thy1.1 by CD4+Vβ4+ polarized Th17 cells (left panels). The right 
panels show the expression of CXCR3 by Thy1.1+CD4+Vβ4+ polarized Th17 
cells. (B) shows diabetes incidence of mice recipient of Th17 cells described in 
(A) (n = 4 per group). (C) shows production of IFNγ and IL-17 by CXCR3-
transduced CD4+Vβ4+Thy1.1+ cells before and 7 days after transfer. The results 
in (A-C) are representative of 3 independent experiments. (D) NOD.scid mice 
recipient of CXCR3- or empty vector-transduced Th17 cells were treated with Ig-
HEL or Ig-p79 (n = 4 per group) and monitored for diabetes. Data depicts 
diabetes incidence.  The experiment was performed twice with consistent results. 
 
Th17 cells are unable to undergo Th1 conversion upon transfer into NOD 
mice and require depletion of Tregs to transfer diabetes to the host.  
The fact that Th17 cells need to convert into Th1 cells to induce T1D in the 
lymphopenic environment puts into question that whether Th17 cells can be 
pathogenic in a non-converting environment. Because Th17 cells maintained 
their stability in normal but not lymphopenic B6 mice (Nurieva et al., 2009), we 
first tested the stability of BDC2.5 Th17 cells in normal NOD recipients. To 
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distinguish from the endogenous CD4+Vβ4+ T cells, Th17 cells were labeled with 
CFSE and transferred into 4-wk female NOD mice. The choice of CFSE labeling 
is based on the observation that Th17 cells did not undergo significant 
proliferation in NOD mice over a kinetic 7-day monitoring period (data not 
shown), therefore the CFSE labeling was maintained stable to mark the distinct 
population of the transferred Th17 cells (Fig. 8A). As expected, the transferred 
Th17 cells (CD4+Vβ4+CFSE+) mainly produced IL-17 (Fig. 8A), indicating that in 
vitro generated BDC2.5 Th17 cells stayed stable in normal NOD hosts. We next 
examined the islet inflammation by histology, and found that Th17 transfer 
induced remarkable lymphocyte infiltration in the islets (Fig. 8B). However, the 
stable Th17 cells did not induce hyperglycemia during a 21-day monitoring 
period, while transfer of Th1 cells rapidly induced elevated blood glucose levels 
in the host NOD mice (Fig. 8C), suggesting an inability of Th17 cells to induce 
clinical diabetes in a normal environment.  
Because regulatory T cells (Tregs) have been shown to be able to suppress 
Th17 cells (Chaudhry et al., 2009; Chaudhry et al., 2011; Huber et al., 2011), we 
wondered if depletion of Tregs in the NOD hosts would accelerate the transition 
of insulitis to clinical diabetes following Th17 cell transfer. To test this premise, 
we utilized NOD.FoxP3GFP.DTR mice as hosts, and injected diphtheria toxin (DT) 
before and after Th17 transfer to conditionally deplete FoxP3+ Tregs. As shown 
in Fig. 8D, induction of clinical diabetes was not observed in mice given DT or 
Th17 cells alone, whereas as high as 75% of the mice recipient of both Th17 
cells and DT injections developed clinical diabetes (peaked at day 11 post 
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transfer). Thus, stable Th17 cells trigger pancreatic inflammation without clinical 
diabetes in the NOD mouse but depletion of Tregs sustains transition to overt 
diabetes.  
 
Figure 8.  Ig-p79 ameliorates islet histopathology and clinical diabetes 
caused by transfer of Th17 cells into NOD mice. (A) CFSE-labeled Th17 cells 
were transferred into 4-wk-old female NOD mice and 7 days later, the splenic 
cells were stimulated with p79 peptide for 16h. The cells were stained with anti-
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Vβ4 and anti-CD4 antibodies and then stained for intracellular IFNγ and IL-17 
cytokines. The plot shows IFNγ and IL-17 production by CD4+CFSE+Vβ4+ T cells.  
The results are representative of 3 independent experiments. (B) shows H&E 
staining (100X magnification) of non-serial pancreatic sections (200µm apart) 
from NOD mice that did not receive T cell transfer (No transfer, n = 3) or mice 
recipient of either Th1 or Th17 polarized cells (n = 6 per group). (C) shows blood 
glucose levels (mg/dl) of individual NOD mice recipient of either Th1 or Th17 
polarized cells (n = 5 per group). (D) shows incidence of diabetes in 
NOD.FoxP3GFP.DTR mice recipient of Th17 cells (n = 8 per group) that were 
treated with DT (Th17 + DT) or PBS (Th17 + PBS).  A group treated with DT 
without transfer of Th17 cells (DT, n = 3) was included for control purposes. (E) 
shows representative H&E staining and islet infiltration severity scores (bar 
graph) of NOD mice recipient of Th17 cells and treated with Ig-p79 or Ig-HEL (n = 
6 per group). The scoring system is described in Materials and Methods. The 
percentages represent the number of islets with a specific score over the total 
number of islets (30-40 per pancreas). (F) shows incidence of diabetes in Treg-
depleted (by DT) NOD.FoxP3GFP.DTR mice recipient of Th17 cells and treated with 
Ig-p79 or Ig-HEL (n=10 per group). (G) shows the frequency of 
CFSE+CD4+Vβ4+ T cells recovered from pancreatic islets of NOD or Treg-
depleted NOD.FoxP3GFP.DTR mice recipient of Th17 transfer and treated with Ig-
p79 or Ig-HEL. All pancreatic histology and flow cytometry analyses (B, E, G) 
were performed on day 7 post T cell transfer. The results in each panel are 
representative of 2 or 3 independent experiments.  
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Treatment with Ig-p79 suppresses both islet pathology and clinical 
diabetes induced by stable Th17 cells. 
To determine whether the non-convertible Th17 cells can be tolerized by Ig-p79, 
the NOD mice recipient of Th17 cells (without depletion of Tregs) were given Ig-
p79 and assessed for pancreatic inflammation. The findings indicate that cell 
infiltration was significantly reduced in Ig-p79- relative to Ig-HEL-treated mice 
(Fig. 8E). In fact, the majority (57%) of the islets in Ig-p79-treated mice had 
minimal infiltration (No insulitis). 25% of the remaining islets had peri-insulitis and 
only 18% had intra-insulitis. In contrast, in untreated and Ig-HEL-treated mice, 
most of the islets (51% and 65%, respectively) displayed intra-insulitis (Fig. 8E). 
Furthermore, Ig-p79 but not the control Ig-HEL was able to suppress clinical 
diabetes when given to DT-treated (Treg depleted) NOD.FoxP3GFP.DTR mice 
recipient of Th17 cells (Fig. 8F). Analysis of Th17 relocation to the pancreas 
upon treatment with Ig-p79 indicated the presence of a minimal frequency of 
CFSE-labeled cells relative to Ig-HEL treatment (Fig. 8G). Thus, Ig-p79 is able to 
suppress both forms of disease. 
 
Apoptosis of stables Th17 cells represents the mechanism of the tolerance 
induced by treatment with Ig-p79. 
We reasoned that the minimal presence of Th17 cells in the pancreas of Ig-p79-
treated mice (Fig. 8G) could be due to impaired trafficking and or cell death in 
other organs. To address this issue, we searched for the Th17 cells in both the 
spleen and PLN of Treg-depleted (DT-Foxp3DTR) as well as un-depleted mice. 
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The results show that very few cells were present in the spleen in Ig-p79-treated 
relative to untreated or Ig-HEL-treated mice (Fig. 9A). Moreover, by day 2 post 
treatment the numbers of Th17 cells decreased significantly in the spleen and 
PLN relative to Ig-HEL treatment in both strains (Fig. 9B). In fact, by day 7 the 
Th17 cells were barely detectable in either organ. The treatment with Ig-p79 did 
not induce conversion because there was no Th1 cells in the PLN of either strain 
and the very few residual cells were IL-17-producing cells like the untreated or Ig-
HEL treated mice (Fig. 9C). Overall, Ig-p79 did not induce conversion but 
reduced the number of Th17 cells in the spleen and PLN.  
Since the number of Th17 cells diminished gradually both in the spleen and PLN 
and the cells were barely found in the pancreas, it is likely that Ig-p79 drives 
death of the cells rather than conversion to Th1 or interference with trafficking. 
Indeed, when the splenic non-convertible Th17 cells were analyzed for 
incorporation of 7 amino-actinomycin D (7-AAD) on day 2 after transfer to the 
hosts, there was a significant  incorporation of 7-AAD by the Th17 cells in both 
NOD and DT-NOD.FoxP3DTR mice, indicating that the cells are undergoing 
apoptosis (Fig. 9D). The untreated or Ig-HEL-treated mice had much less 
incorporation of 7-AAD. Like in the spleen, significant 7-AAD incorporation was 
also observed in the PLN (Fig. 9E). Incorporation of 7-AAD continued at a similar 
level on day 7, indicating that the residual cells are undergoing death at a 
significant rate. Furthermore, in the Ig-p79-treated mice, the cells displayed an 
increased level of FasL but decreased expression of RORγt relative to untreated 
or Ig-HEL-treated mice (Fig. 9F). Since RORγt functions as a negative regulator 
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for FasL (He et al., 1998), it is likely that its down-regulation in Th17 cells led to 
the up-regulation of FasL, the trigger of a signaling cascade that sustains 
apoptosis (Fang et al., 2010; Zhang et al., 2008). Collectively, these results 
indicate that stable Th17 cells undergo apoptosis upon treatment with Ig-p79. 
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Figure 9. Apoptosis of stable Th17 cells represents the mechanism 
underlying amelioration of clinical and histopathological diabetes by Ig-
p79.  NOD or Treg-depleted NOD.FoxP3GFP.DTR mice recipient of CFSE-
labeled Th17 cells were treated with Ig-p79 or Ig-HEL and the spleens or PLN 
were harvested at the indicated time points.  (A) shows the frequency of Th17 
cells on day 2 after treatment with Ig-p79 or Ig-HEL (n = 2 for each time). A group 
of mice that did not receive any treatment (Untreated) is shown for control 
purposes. (B) shows the absolute cell number of CD4+CFSE+ cells in spleen and 
PLN on day 2 and 7 post transfer. The numbers represent the mean ± SEM of 6 
mice.  ** P < 0.01. * P < 0.05. (C) shows the production of intracellular IFNγ and 
IL-17  by  CD4+Vβ4+CFSE+ T cells from the PLN that were harvested on day 7 
post transfer and stimulated with p79 peptide. (D) shows 7-AAD binding by 
splenic cells from the mice described in  (A).  (E) shows the percentage of 7-
AAD+ cells from spleen and PLN on day 2 and 7 post transfer of CFSE-labeled 
Th17 cells. The percentages represent the mean ± SEM of 6 mice.  ** P < 0.01. * 
P < 0.05.  (F) shows FasL (left panels) and RORγt (right panels) expression by 
CD4+Vβ4+CFSE+ cells on day 2 for untreated, Ig-p79- or Ig-HEL- treated mice (n 
= 2 for each time) post Th17 transfer. The results in each panel are 
representative of 3 independent experiments. 
 
Ig-p79-induced apoptosis is specific for Th17 but not Th1 cells. 
The fact that Ig-p79 induced Th17 apoptosis in normal NOD hosts led us to 
further explore if apoptosis can be induced to Th1 cells in the same host. 
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Transfer of Th1 cells induced rapid onset of clinical diabetes in 4-wk female NOD 
mice with Ig-HEL treatment, while Ig-p79 treatment completely suppressed the 
Th1-mediated diabetes (Fig. 10A). The Ig-p79-treated Th1 cells were present at 
a  much higher frequency (2.4%) in spleen than the Ig-HEL-treated controls 
(0.25%) on day 2 after transfer, indicating that these cells preferentially 
accumulated in the spleen (Fig. 10B). Furthermore, the Ig-p79-treated Th1 cells 
displayed a low level of 7-AAD incorporation (5.6±0.7%) which was comparable 
to the Ig-HEL-treated controls (5.8±1.2%) (Fig. 10C), suggesting that Ig-p79 did 
not increase the apoptotic level of the Th1 cells. Moreover, 63±4.2% of the Ig-
p79-treated Th1 cells had lower CXCR3 expression than the Ig-HEL-treated 
controls (Fig. 10D), indicating the dampened trafficking ability of these Th1 cells. 
Thus, unlike Th17 cells, Ig-p79 did not induce significant apoptosis to Th1 cells, 
and the Ig-p79-mediated CXCR3 downregualtion on Th1 cells is consistent 
between normal and lymphopenic environment. 
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Figure 10. Polarized Th1 cells transferred into NOD mice down-regulate 
CXCR3 expression upon treatment with Ig-p79. CFSE-labeled polarized Th1 
cells were transferred into NOD mice and 24h later the hosts were given Ig-p79 
or the control Ig-HEL.  (A) shows incidence of diabetes in both groups of mice (n 
= 6 per group). (B-D) The frequency of splenic CD4+CFSE+ cells (B), their 
apoptosis (C) and CXCR3 expression (D) was analyzed on day 2 after T cell 
transfer.  The numbers indicate the mean ± SEM of 6 mice.  Each panel is 
representative of 3 independent experiments. 
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DISCUSSION 
Although T1D has been long viewed as a Th1-driven disease, the discovery of 
Th17 cells has challenged these studies and provides a new avenue for further 
exploring the roles of this helper T cell subset during T1D development. 
However, due to different experimental models and approaches, controversial 
results have been obtained, resulting in obscure understandings as to whether 
Th17 cells are required or involved in T1D pathogenesis. A recent study 
supported a negative role of the IL-17 cytokine in T1D (Joseph et al., 2012). By 
generating an IL-17 knockdown (IL-17 KD) NOD mouse model using RNA 
silencing, it was shown that these IL-17 KD NOD mice had a very similar disease 
development with the WT counterparts. These results seemed to indicate that 
Th17 cells are dispensable throughout T1D development. However, because this 
study only used blood glucose levels as the readout of the disease development 
without analyzing islet inflammation, it is still possible that IL-17 plays a role in 
the course of insulitis, but the cytokine alone cannot drive the transition to 
hyperglycemia. This is supported by the findings that anti-IL-17A and anti-17E 
(IL-25) neutralizing antibodies were able to curtail islet infiltration and reduce the 
formation of GAD65 autoantibodies (Emamaullee et al., 2009). In fact, in the 
present study we provide evidence showing that in vitro polarized BDC2.5 Th17 
cells are able to trigger cell infiltration but not overt T1D in young NOD recipients. 
Furthermore, the transition of insulitis to critical β-cell damage is tightly checked 
by the host Tregs in that depletion of Tregs resulted in development of 
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hyperglycemia. Therefore, Th17 cells could be more involved in the insulitis 
stage rather than direct killing of β cells. 
Furthermore, the disease stage in which IL-17 is targeted is crucial for the 
effectiveness of the intervention and interpretation of the results. For example, 
anti-IL-17A antibodies delayed T1D onset in NOD mice only when given at the 
10-wk-old of age but not before 5-wk-old or after diabetes onset. Interestingly, 
treatment with anti-IL-17E antibodies was able to reduce the blood glucose levels 
in mice with already established hyperglycemia (Emamaullee et al., 2009). 
Therefore, the function of the IL-17 family should be carefully dissected and 
analyzed at different disease stages. This would require studies using genetic 
approaches to induce selective ablation the individual IL-17 cytokines on a 
temporal basis. In this sense, the Cre-ER system (driven by a T cell specific 
promoter) in which injection of tamoxifen induces nuclear relocation of the Cre 
recombinase and the subsequent deletion of the IL-17 DNA fragment flanked by 
two Loxp sites will be helpful. However, it should be noted that analyzing or 
targeting the IL-17 cytokines does not necessarily represent the role of the bona 
fide Th17 cells in vivo especially since Th17 cells are able to produce various 
inflammatory cytokines including IL-21. In fact, IL-21 receptor-deficient NOD mice 
did not develop insulitis or diabetes and displayed reduced IL-17 production in 
the spleen or PLN (Spolski et al., 2008). Thus, experiments with depletion of the 
bona fide Th17 cells rather than a certain Th17-associated cytokine would be 
required to address these issues.  
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Another difficulty to analyze the genuine in vivo generated Th17 cells is their 
plasticity. In the present study we observed that in vitro generated BDC2.5 Th17 
cells maintained their lineage commitment in NOD hosts, but these results should 
not repute the possibility that polyclonal Th17 cells may convert into other 
effector T cell subsets in vivo. Indeed, in vivo generated Th17 cells are 
convertible in presence of IFNγ and IL-12. (Lexberg et al., 2010). In addition, 
despite the fact that IL-17+ cells can be detected in advanced stages of T1D, 
their frequency is much lower than the IFNγ+ counterparts (Jain et al., 2008; 
Martin-Orozco et al., 2009), indicating that Th17 cells may have converted into 
Th1 cells in pre-diabetic stages. Elaborating these issues requires genetic 
tracking of the in vivo generated Th17 cells throughout T1D development. In this 
case, the fate mapping system (IL-17-Cre crossed with Rosa26-Loxp-Stop-YFP) 
used for monitoring Th17 cells in EAE (Hirota et al., 2011) should be of great 
value. These studies would provide important clinical implications in that the 
plasticity of Th17 cells should be considered for design of treatment targeting 
typical Th17-associated factors, such as neutralization of IL-17 and IL-22 
cytokines because these factors may not be the major mediators in a certain 
disease stage when Th17 cells convert into other effector cell types.  
Given that plasticity is an important mechanism that Th17 cells use to exert their 
pathogenic functions, tolerance of the Th17 cells should be analyzed under both 
converting and non-converting circumstances. Interestingly, we found that the 
mechanism or phenotype of tolerance is shaped by the final transcription factors 
of the effector T cells. This is likely a direct effect of the Ig-p79 treatment through 
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engagement with the T cell receptor without costimulatory signaling in both Th1 
and Th17 cells, and the downstream “tolerogenic” signaling leads to interruption 
of T-bet and RORγt, respectively. Further studies are required to dissect the 
signaling events between TCR/CD28 (i.e. PI3K/AKT/Ras-MAPK) and the 
JAK/STAT pathways (i.e. STAT4/T-bet or STAT3/ RORγt) upon tolerance 
induction. This is important in that our tolerogenic model is established with 
minimal involvement of Tregs. In the converting system, we removed FoxP3+ 
cells before transfer and we did not detect any FoxP3+ cells during tolerance 
induction and disease suppression (data not shown). In the non-converting 
system, Ig-p79 treatment was able to overcome clinical diabetes when the host 
Tregs are depleted. These results suggest that effective tolerance can be 
established using intrinsic mechanisms without assistance of Tregs. The 
implication here would be particularly useful when facing autoimmune situations 
associated with dysfunction of Tregs, including T1D (Lindley et al., 2005).    
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CHAPTER III 
RECOVERY FROM OVERT TYPE 1 DIABETES ENSUES 
WHEN IMMUNE TOLERANCE AND β-CELL FORMATION 
ARE COUPLED WITH REGENERATION OF 
ENDOTHELIAL CELLS IN THE PANCREATIC ISLETS 
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ABSTRACT 
Immune modulation of pancreatic inflammation induces recovery from type 1 
diabetes (T1D) but remission was not durable perhaps due to an inability to 
sustain the formation and function of new pancreatic β-cells. We have previously 
shown that Ig-GAD2, carrying glutamic acid decarboxylase (GAD) 206-220 
peptide, induced in hyperglycemic mice immune modulation that was able to 
control pancreatic inflammation, stimulate β-cell regeneration and prevent T1D 
progression. Herein, we show that the same Ig-GAD2 regimen given to mice with 
overt T1D is unable to reverse the course of disease despite eradication of Th1 
and Th17 cells from the pancreas. However, the regimen is able to sustain 
recovery from T1D when Ig-GAD2 was accompanied with transfer of bone 
marrow (BM) cells from healthy donors. Interestingly, alongside immune 
modulation there was concomitant formation of new β and endothelial cells in the 
pancreas. The new β-cells were of host origin while the donor BM cells gave rise 
to the endothelial cells. Moreover, transfer of purified BM endothelial progenitors 
instead of whole BM cells sustained both β and endothelial cell formation and 
reversal of diabetes. Thus, overcoming T1D requires both immune modulation 
and repair of the islet vascular niche to preserve newly formed β-cells.  
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INTRODUCTION 
T1D is a chronic disease in which the insulin-producing β-cells of the pancreatic 
islets are destroyed by inflammatory T lymphocytes of the immune system 
(Atkinson and Eisenbarth, 2001; Bluestone et al., 2010). Broad-based T-cell-
targeted therapies, such as anti-CD3 monoclonal antibodies, were able to 
reverse established T1D in the NOD mouse (Belghith et al., 2003). In humans 
however, while the regimen preserved C-peptide responses, disease remission is 
not sustained perhaps due to return of inflammation after termination of the 
treatment (Herold et al., 2005; Herold et al., 2002). In addition, non-specific 
targeting of the T cells may compromise the normal function of the immune 
system against pathogen infections (Chatenoud and Bluestone, 2007; Waldron-
Lynch and Herold, 2011). Therefore, antigen-specific modulation strategies 
aiming at re-establishing the self-tolerance of the immune system to β-cell-
associated antigens are highly desired and have shown efficacy in the non-obese 
diabetic (NOD) mouse and initial human clinical trials (Moody et al., 1995; 
Waldron-Lynch and Herold, 2011). In fact, patients with a recent onset of T1D 
demonstrated improved C-peptide responses after vaccination with the glutamic 
acid decarboxylase 65 (GAD65) protein (Ludvigsson et al., 2008), a well-defined 
self-antigen involved in T1D development (Kaufman et al., 1993; Nepom et al., 
2001; Tisch et al., 1993). Moreover, T cell responses against GAD65 can be 
detected in NOD mice and T1D patients (Ellis and Atkinson, 1996; Tisch et al., 
1993), and prevention of GAD65 expression in pancreatic islets blocked T1D 
development in NOD mice (Yoon et al., 1999). Several different CD4+ T cell 
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epitopes derived from GAD65 have been further characterized (Chen et al., 
2003; Kim et al., 2004; Liu et al., 2000; Tarbell et al., 2002), among which the 
amino acid sequence 206-220 of GAD65 (p206) is considered a late-stage 
determinant (Chao et al., 1999). T cells that specifically recognize p206 produced 
immunoregulatory cytokines IFNγ and IL-10 and were able to delay the onset of 
T1D when co-transferred with diabetogenic T cells (Kim et al., 2004). To 
effectively present this peptide in vivo and amplify its inhibitory function, we 
previously inserted the p206 sequence on an immunoglobulin (Ig) molecule (Jain 
et al., 2008). The resulting Ig-GAD206-220, referred to as Ig-GAD2, halted 
progression of T1D when given to NOD mice that began to develop 
hyperglycemia (blood glucose levels (BGL), 160~250 mg/dl) (Jain et al., 2008). 
The disease suppression in these hyperglycemic mice is manifested by 
eradication of islet infiltration, stimulation of β-cell division, and generation of 
healthy islets (Jain et al., 2008). However, the effectiveness of Ig-GAD2 
treatment in reversal of overt T1D is yet to be defined. 
To this end, we administered Ig-GAD2 to mice with a BGL ≥ 300mg/dl for two 
consecutive measurements. While the regimen was effective at the 
hyperglycemic stage (BGL, 160~250 mg/dl), it did not reverse the course of the 
disease in the diabetic mice (BGL ≥ 300mg/dl). Intriguingly, we observed 
curtailed islet infiltration and diminished pathogenic Th1 and Th17 cells in the 
diabetic mice given Ig-GAD2. These results suggest that a single antigen-specific 
regimen may lack sustainable disease remission and should be applied in 
combination with other agents that could promote β-cell survival and growth. In 
97 
 
fact, it has been shown that adult β-cells are formed mainly by self-duplication in 
healthy or pancreatectomized mice (Dor et al., 2004). Therefore, the lack of 
recovery from T1D may be related to an inability of the residual β-cells to 
replicate. Since BM transplantation in the absence of inflammation induced 
regeneration of endogenous β-cells and restored normoglycemia in mice with 
streptozotocin (STZ)-induced pancreatic injury (Hess et al., 2003; Mathews et al., 
2004), we sought to determine whether enrichment with BM cells during 
suppression of inflammation with Ig-GAD2 would counter overt diabetes.  
Our results demonstrate that sustainable reversal of overt T1D can be achieved 
by transferring BM cells during treatment with Ig-GAD2. The recovered mice 
displayed a concomitant restoration of the insulin-producing β and endothelial 
cells (ECs) in the pancreatic islets. Interestingly, while the restored β-cells were 
of host origin, there was a marked pancreatic engraftment of the donor BM-
derived endothelial cells in the diabetes-free mice. Furthermore, transfer of 
purified BM endothelial progenitors (EPCs) instead of the whole BM was able to 
support the protection against T1D along with Ig-GAD2 treatment. Because islet 
endothelial cells are critical for fine-tuning of β-cell development and function 
(Cleaver and Melton, 2003; Johansson et al., 2006; Kaido et al., 2004; Lammert 
et al., 2001; Nikolova et al., 2006), and diabetes course leads to dysfunction of 
both EPCs and mature ECs (Caballero et al., 2007; Khoo et al., 2009; Loomans 
et al., 2004; Schatteman et al., 2000; Thum et al., 2007), our findings have 
clinical implications by emphasizing the need for repair of islet endothelial cells 
along with control of immune inflammation in order to overcome overt T1D. 
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RESEARCH DESIGN AND METHODS 
 
Mice 
NOD and NOD.GFP mice expressing the green fluorescence protein under the β-
actin promoter were previously described (Wallet et al., 2009) were maintained in 
the Animal Facility at the Medical Sciences Building under barrier conditions.  All 
animals were used according to the guidelines of the University of Missouri 
Animal Care and Use Committee. 
 
Treatment with Ig-GAD2 and donor BM 
Mice began BGL monitoring at 10 weeks of age, and those who displayed ≥300 
mg/dl for 2 consecutive weeks were enrolled in the treatment regimen. The mice 
were first given 2 sustained release insulin implants (LinShin, Toronto, Ontario, 
Canada) inserted subcutaneously in the abdomen to temporarily maintain 
normoglycemia for 2-3 weeks. The mice were then given 300 µg Ig-GAD2 
intraperitoneal (i.p.) 3 times weekly for 5 weeks and then once a week for 
another 5 weeks. Donor BM cells were isolated from the femur and tibia, and 10 
x 106 whole BM cells were transferred intravenously (i.v) weekly on week 2, 3, 
and 4 post diagnosis. The mice were monitored for BGL until day 120. 
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Treatment with Ig-GAD2 and donor EPCs 
This regimen was similar to treatment with Ig-GAD2 and donor BM except that 
EPCs substituted for whole BM cells. FLK-1+ EPCs were given at 5 x 104 per 
injection while FLK-1− EPCs were given at 3 x 106 cells per injection. 
 
Purification of EPCs 
BM cells were harvested from healthy or diabetic (sick) mice and depleted of 
lineage+ (Lin+) cells using the lineage cell depletion kit according to 
manufacturer’s instruction (Miltenyi Biotec). The Lin− cells were stained with anti-
c-Kit, and anti-FLK-1 antibodies as well as with 7-amino-actinomycin D (7-AAD) 
and sorted into c-Kit+7-AAD−FLK-1+ or c-Kit+7-AAD−FLK-1− cells.  
 
Cell surface staining 
For detection of PECAM1, FLK-1, c-Kit and CD45 the cells were stained with 
marker-specific antibodies, including phycoerythrin (PE)-cy7-conjugated anti-
PECAM1 (390), allophycocyanin (APC)-conjugated anti-FLK1 (Avas12a1) (both 
from eBiosciences), PE-cy7-conjugated anti-c-Kit (2B8) and APC-cy7-conjugated 
anti-CD45 (2D1) (both from BD Pharmingen) antibodies. For detection of 
apoptotic cells, cells were stained with 7-AAD (EMD Biosciences).  
 
Intracellular staining 
For detection of intracellular IFNγ, IL-10 and IL-17 in CD4+ T cells, the cultures 
were stimulated with PMA (50ng/ml) and ionomycin (500ng/ml) for 4h in 
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presence of Brefeldin A (10µg/ml), and then stained with Peridinin-chlorophyll-
protein (PerCP)-cy5.5-conjugated anti-CD4 (RM4-5), PE-conjugated anti-
Vβ8.1/8.2 (MR5-2) and FITC-conjugated anti-CD8 (RPA-T8) antibodies (all from 
BD Pharmingen). Subsequently, the cells were fixed with 2% formaldehyde, 
permeabilized with 0.2% saponin and stained with PE-cy7-conjugated anti-IFNγ 
(XMG1.2), APC-conjugated anti-IL-10 (JES5-16E3) or APC-conjugated anti-IL-17 
(eBio17B7) antibodies (all from eBiosciences).  
 
Flow cytometry analyses 
The samples were read using a Beckman Coulter CyAn ADP and data were 
analyzed using Summit V4.3 (Dako). Cell sorting (> 98% purity) was performed 
using a Beckman Coulter MoFlo XDP sorter. 
 
Sample preparation for histological analyses 
Pancreata were frozen in tissue freezing medium (Triangle Biomedical 
Sciences), and non-serial 8-µm thick sections were cut 150-µm apart to avoid 
over counting of the labeled cells. The sections were fixed in 4% formaldehyde 
for 10 min before histological procedures. For detection of enhanced GFP 
expression in tissues, pancreata were fixed in 4% formaldehyde for 4h at 4°C 
and immersed in 30% sucrose overnight before freezing. Analysis of insulitis 
used H&E staining as previously described (Jain et al., 2008). Each experiment 
used 3-6 sections per pancreas.   
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Immunohistochemistry 
For detection of β-cells, pancreatic sections were incubated with HRP-conjugated 
anti-insulin affibody molecule (Abcam, 1:200) at room temperature (RT) for 
45min, and the insulin+ cells were identified by incubating the slides with DAB 
chromogen and substrate (ScyTek) for 5 min. The cell nuclei were 
counterstained with hematoxylin. 
 
Immunofluorescence 
Pancreatic sections were treated with a PBS solution containing 1% BSA, 10% 
goat or donkey serum, and 0.2% Triton-X100 at RT for 1h. The sections were 
then incubated overnight at 4°C with primary antibodies, including rabbit anti-
insulin (Santa Cruz, 1:200), guinea pig anti-insulin (Abcam, 1:300), rabbit anti-
PECAM1 (Abcam, 1:100), goat anti-PECAM1 (Santacruz, 1:100), rabbit anti-ki-
67 (Abcam, 1:300) and goat anti-VEGF (Santa Cruz, 1:200). The slides were 
washed with 3 changes of 0.02% Triton-X100 in PBS and then stained for 1 hour 
at RT with the corresponding secondary antibodies, including Texas Red-
conjugated goat anti-rabbit IgG (1:200), fluorescein isothiocyanate (FITC)-
conjugated goat anti-guinea pig IgG (1:200), FITC-conjugated donkey anti-goat 
IgG (1:200)  (all from Santa Cruz), DyLight 405-conjugated donkey anti-rabbit 
IgG (1:200) and DyLight 549-conjugated donkey anti-goat IgG (1:300) (all from 
Jackson ImmunoResearch). In some experiments, the cell nuclei were 
counterstained with DAPI (Santa Cruz). The images were visualized and 
acquired with a Zeiss fluorescence microscope or an Olympus DSU confocal 
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microscope. The number of β-cells, islets, and endothelial cells was scored with 
a computer-assisted Image Pro Plus program. β-cell mass was calculated as 
described (Sreenan et al., 1999). 
 
Laser capture microdissection 
Pancreatic sections were stained with insulin or PECAM1 and thoroughly 
dehydrated with the Arcturus dehydration component. The insulin+ or PECAM1+ 
cells were dissected with the CapSure HS LCM caps and the Autopix 100 laser 
capture microdissection system by following the manufacturer’s instructions. For 
each individual mouse, cells were dissected from 3-10 non-serial sections. 
Genomic DNA was extracted from the dissected cells using the PicoPure DNA 
extraction kit. All the reagents are from Applied Biosystems. 
 
Detection of Y chromosome by PCR 
Detection of Y chromosome and beta-actin was performed using 20 ng DNA 
template and Maxima qPCR master mix (Fermentas). The primer sequences are 
as follows: Y chromosome, Forward, 5’-GGTGAGAGGCACAAG 
TTGG-3’, Reverse, 5’-ATCTCTGTGCCTCCTGGAAA-3’; Beta-actin, Forward, 5’-
GCTTCTTTGCAGCTCCTTCGTTGC-3’, Reverse, 5’-
GTGTCCGTTCTGAGTGATCC 
TCAG-3’. 
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Measurement of β-cell mass  
The pancreata were isolated and weighted before staining of insulin by 
immunohistochemistry. The insulin positive area relative to the whole section 
area was calculated with the Image Pro Plus program over non-serial sections 
(150 µm apart). The β-cell mass is expressed in mg by multiplying the pancreatic 
weight (mg) with the relative insulin positive area (%).  
 
Quantitative PCR analysis 
Total RNA was extracted from pancreatic islets using the TRI RNA isolation 
reagent (Sigma). Quantitative PCR was performed using the Power SYBR Green 
kit and the StepOnePlus instrument (all from Applied Biosystems). The relative 
quantity (RQ) was calculated based on the ∆∆CT after normalization with the 
internal control 18S ribosome RNA expression. Primer sequences are as follows: 
angpt1, Forward, 5’- AGCATCTGGAGCATGTGATGGA-3’, Reverse, 5’- 
TATCTCAAGCAT 
GGTGGCCGT-3’; angpt2, Forward, 5’- AACACCGAGAAGATGGCAGTGT-3’, 
Reverse, 5’- AGACAAACTCATTGCCCAGCCA-3’; cdh5, Forward, 5’- 
TTCGCACCA 
GGTATTCAACGCA-3’, Reverse, 5’- TCATCTGCATCCACTGCTGTCA-3’; flt1, 
Forward, 5’- TGCAGGAAACCACAGCAGGAA-3’, Reverse, 5’- 
TTCAATGTTGCAG 
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GCGAGCCAT-3’; tie1, Forward, 5’- CAGCATGAAACTTCGCAAGCCA-3’, 
Reverse, 5’- TGGGCACTTCAAACTCTGCTGT-3’; vegfa, Forward, 5’- 
TGCAGGCTGCTGTA 
ACGATGAA-3’, Reverse, 5’- TGCTGTGCTGTAGGAAGCTCAT-3’; tbx21, 
Forward, 5’-TCCAAGTTCAACCAGCACCAGA-3’, Reverse, 5’-
TCCACCAAGACCACATCCA 
CAA-3’; rorc, Forward, 5’-ACAGCCACTGCATTCCCAGTTT-3’, Reverse, 5’-
TCTCGGAAGGACTTGCAGACAT-3’. 
 
Statistical analyses 
P values associated with all pair wise comparisons were calculated based on 
Student’s t-test for independent groups.  
 
 
 
 
 
 
 
 
 
 
 
105 
 
RESULTS 
Ig-GAD2-driven immune modulation is not sufficient to overcome overt 
T1D. 
Our previous work tested the effectiveness of Ig-GAD2 treatment in prevention of 
mice at the hyperglycemic stage (BGL 160~250 mg/dl) from progressing into the 
overtly diabetic stage (BGL ≥ 300 mg/dl) (Jain et al., 2008). The mechanisms 
underlying the protection is the induction of T cell tolerance characterized by 
increase of the IFNγ and IL-10 production by the GAD206-220-specific T cells in 
the periphery but the diminished IL-17 and IFNγ production in the pancreatic 
islets (Jain et al., 2008). We next aimed to investigate whether the same Ig-
GAD2 treatment regimen was able to reverse the course of the overtly diabetic 
mice, which would be more relevant to human circumstances. In an initial 
attempt, we injected Ig-GAD2 chimeras to diabetic mice following the regimen 
that we used for hyperglycemic mice (Jain et al., 2008). The results show that Ig-
GAD2 treatment was able to restrain the BGL of the hyperglycemic mice and 
none of the mice had a BGL above the 300 mg/dl cut-off (Fig. 1A, left panel). In 
contrast, there was no reduction of BGL for all the enrolled diabetic mice (Fig. 
1A, right panel). These results are surprising because Ig-GAD2 was able to 
induce T cell tolerance in the diabetic mice despite the fact that these mice were 
not recovered from the disease. Specifically, the Ig-GAD2-treated diabetic mice 
had increased frequency of CD4+CD8−Vβ8.1/8.2+ T cells producing IFNγ and/or 
IL-10 (Fig. 1B), but diminished IL-17-producing cells in the spleen (SP) and 
pancreatic lymph nodes (PLN) relative to untreated sick animals (Fig. 1C). 
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Moreover, there were reduced Th1 or Th17 cells in the pancreatic islets because 
the mRNA for their signature transcription factors, T-bet and RORγt respectively, 
were significantly diminished (Fig. 1D). These results suggest immune 
modulation driven by Ig-GAD2 is insufficient to normalize the high level of the 
blood glucose in overtly diabetic NOD mice. 
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Figure. 1. Ig-GAD2 treatment could not overcome overt T1D despite 
induction of immune tolerance. (A): Hyperglycemic and diabetic NOD mice (6 
per group) were given Ig-GAD2 and their blood glucose levels (BGL) were 
monitored for a period of 70 days. (B-C): The mice of the diabetic group were 
sacrificed on day 70 and the spleen (SP) and pancreatic lymph node (PLN) cells 
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were harvested, stimulated with PMA and ionomycin and stained for surface 
CD4, CD8 and Vβ8.1/8.2 as well as intracellular IFNγ, IL-10 and IL-17. A group 
of mice sacrificed upon diagnosis of diabetes (untreated) is used as control. (B) 
shows representative FACS plots (top) and individual mice (bottom) depicting 
CD4+CD8−Vβ8.1/8.2+ cells producing IFNγ and IL-10. (C) Shows the frequency of 
CD4+CD8−IL-17+ cells. (D) Shows the relative quantity (RQ) of mRNA expression 
for RORγt (rorc) and T-bet (tbx21) in the pancreatic islets of untreated and Ig-
GAD2 treated mice. Each bar represents mean ± SEM of 3-6 mice. ** P < 0.01, * 
P < 0.05. 
 
Transfer of BM cells alongside Ig-GAD2 treatment overcomes overt T1D.  
Because β-cells are formed mainly by self-duplication (Dor et al., 2004), and 
every β-cell displayed an equal ability to proliferate (Brennand et al., 2007), the 
lack of disease recovery in diabetic mice may be related to an inability of the very 
few residual β-cells to replicate. We reasoned that approaches that may facilitate 
β-cell division should be provided as an accessory therapy with Ig-GAD2 
treatment. Since BM transplantation in the absence of inflammation led to 
regeneration of endogenous β cells (Hess et al., 2003; Mathews et al., 2004), we 
sought to determine whether enrichment with BM cells during suppression of 
inflammation with Ig-GAD2 would counter overt diabetes. We then combined BM 
cell transfer from healthy donors with Ig-GAD2 injections and devised a 70-day 
treatment regimen (Figure 2A and Methods). Indeed, the majority of the mice 
given both Ig-GAD2 and BM (Ig-GAD2+BM) had a BGL < 300 mg/dl whether the 
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BM was from male or female donors (Fig. 2B). No protection was observed in 
mice given Ig-GAD2 or BM alone (Fig. 2B). These results suggest that both BM 
transfer and Ig-GAD2 are required to contain the high BGL in overtly diabetic 
mice. Furthermore, the enrichment with BM cells sustained recovery from 
disease without impacting Ig-GAD2-mediated immune modulation. Indeed, the 
diabetic mice treated with the combination (Ig-GAD2+BM) regimen, like those 
recipient of Ig-GAD2 alone (Fig. 1B-D), had increased frequency of 
CD4+CD8−Vβ8.1/8.2+ T cells producing IFNγ and/or IL-10 (Fig. 2C), but 
diminished Th17 cells in the SP and PLN (Fig. 2D). In contrast, mice recipient of 
BM alone which remained sick had no increase in IFNγ- and IL-10-producing 
cells or decrease in Th17 cells (Fig. 2, C and D). Moreover, in the pancreas of Ig-
GAD2+BM groups, the mRNA for T-bet and RORγt was significantly diminished 
relative to animals recipient of BM alone (Fig. 2E), indicating that both Th1 and 
Th17 cells were minimal in this site. Overall, addition of BM transfer to the Ig-
GAD2 regimen sustained recovery from diabetes without impacting immune 
modulation. 
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Figure. 2.  Healthy donor BM cells transferred during immune modulation 
restore normoglycemia in diabetic mice. (A) shows a schematic 
representation of the treatment regimen in which diabetic mice received 2 insulin 
pellet implants on day 1 of the regimen and Ig-GAD2 and BM transfer as 
indicated. (B) shows percent of mice with BGL < 300 mg/dl from groups recipient 
of BM transfer alone (BM), Ig-GAD2 alone (Ig-GAD2), or Ig-GAD2 plus male or 
female BM. n indicates the number of mice. (C-D): The SP and PLN cells of the 
111 
 
mice recipient of BM or Ig-GAD2 + BM were harvested on day 70, stimulated with 
PMA and Ionomycin, and analyzed for cytokine production. (C) shows 
representative FACS plots (left) and individual mice (right) depicting 
CD4+CD8−Vβ8.1/8.2+ cells producing IFNγ and IL-10. (D) Frequency of IL-17-
producing CD4+CD8- cells. (E) shows the RQ of mRNA expression for RORγt 
(rorc) and T-bet (tbx21) in the pancreatic islets of mice recipient of BM or Ig-
GAD2+BM. Each bar represents mean ± SEM of 4-8 mice.  ** P < 0.01, * P < 
0.05. 
 
BM transfer promotes β-cell restoration without affecting immune 
tolerance.  
The protection of the Ig-GAD2+BM treatment regimen against overt T1D is also 
manifested by measurement of the mean BGL. As is shown in Fig. 3A, the 
average BGL of all the 17 mice given by Ig-GAD2+BM is significantly lower 
throughout the 120-day monitoring period as compared to those given Ig-GAD2 
or BM alone. BM transfer from healthy donors may cause innocuous homing of 
non-β-cell autoreactive hematopoietic cells into the islet, leading to abrogated 
immune infiltration and alleviated disease. To test this possibility, we examined 
the level of pancreatic infiltration in mice recipient of different treatment regimens. 
The results show that the majority of the islets in mice given BM alone displayed 
severe insulitis, which was comparable with the control hyperglycemic and 
diabetic mice (Fig. 3, B and C). In contrast, those given Ig-GAD2 alone or Ig-
GAD2+BM had mostly no insulitis or peri-insulitis (Fig. 3, B and C). Thus, 
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treatment with Ig-GAD2 alone was sufficient to suppress the immune infiltration 
in the pancreas, and BM transfer did not contribute to such modulatory activities. 
These results are intriguing because the treatment with Ig-GAD2+BM, but not Ig-
GAD2 alone, was able the reverse diabetes. To determine how Ig-GAD2 and Ig-
GAD2+BM eradicated pancreatic infiltration but yielded different clinical 
outcomes, we compared the effect of the treatments on the pancreatic β-cell 
mass. Indeed, while the mice treated with Ig-GAD2+BM had structured islets with 
abundant insulin-positive cells, those given Ig-GAD2 alone had less islets with 
fewer β-cells like those given BM alone (Fig. 3D). Compiled results indicate a 
significant increase in insulin-producing β-cells, sizeable islets, and β-cell mass in 
Ig-GAD2+BM-treated mice that were not evident in the animals recipient of Ig-
GAD2 or BM alone (Fig. 3, E-G). Overall, these results suggest that that addition 
of BM transfer sustained increase of functional β-cells that were able to thrive 
under minimal inflammation curtailed by Ig-GAD2.  
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Figure. 3. Mice recipient of BM transfer during treatment with Ig-GAD2 
display increased insulin-producing pancreatic β-cells. (A) Blood glucose 
levels (BGL) in mice grafted with insulin pellets and given BM (n=8), Ig-GAD2 
(n=7), or Ig-GAD2 + BM (n=17). (B) Representative H&E staining (100X) of 
pancreatic sections from mice recipient of BM, Ig-GAD2 or Ig-GAD2+BM 
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(sacrificed on day 70) (n=6 per group). Unmanipulated 4-6 week-old healthy 
(BGL ≤140 mg/dl), hyperglycemic (BGL = 160~250 mg/dl), and recent onset 
diabetic (BGL ≥ 300mg/dl) mice are included as control. (C) shows islet 
infiltration severity scores of the indicated groups. (D) shows representative 
immunohistochemistry staining (100X) for insulin (brown) with nuclei 
counterstained with hematoxylin (blue). (E) Quantification of insulin+ cells per 
islet. (F) Number of islets that contain more than 10 insulin+ cells. (G) Mass of β-
cells. Results in (E-G) are based on analysis of 10-50 islets from 3-6 non-serial 
sections per pancreas for 6 mice in each group. Error bars, mean ± SEM. * P < 
0.05, ** P < 0.01.  
 
Donor BM-derived cells contribute to disease remission via indirect 
mechanisms. The observations also raise the question as to whether the 
transferred BM cells serve as a supplemental source of the new β-cells. To test 
this premise, we used BM cells from NOD mice expressing enhanced GFP 
driven by the beta-actin promoter (NOD.GFP) (Wallet et al., 2009) along with Ig-
GAD2 treatment and assessed the insulin-producing β-cells for GFP expression. 
Indeed, there was no GFP/insulin colocalization observed at any time point 
during Ig-GAD2+BM treatment (Fig. 4, left panels). Furthermore, the GFP+ cells, 
which were abundant in the diabetes-free mice, were minimal in those animals 
that received the same regimen but remained diabetic (Fig. 4). Thus, the BM 
transfer did not appear to serve as a source of insulin-producing β-cells but 
yielded engraftment of GFP+ cells in the islets of recovering mice. These results 
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are in agreement with other reports indicating that BM cells or other cell sources 
failed to give rise to functional β-cells during recovery of diabetes (Choi et al., 
2003; Chong et al., 2006; Hess et al., 2003; Lechner et al., 2004; Mathews et al., 
2004; Nishio et al., 2006; Suri et al., 2006), suggesting that the donor GFP+ cells 
contribute to the formation of healthy islets via indirect mechanisms.  
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Figure 4. Insulin producing-β cells in Ig-GAD2+BM-treated mice are not 
derived from donor cells. NOD mice given Ig-GAD2 and BM from NOD.GFP 
117 
 
donors (Ig-GAD2+GFP BM) according to the regimen described in Figure 2 were 
sacrificed on day 30, 60 and 120 post treatment and pancreatic sections from 3 
diabetic or 3 diabetes-free mice were stained for insulin at each time point. Data 
shows representative confocal microscopy visualizing insulin (red) and GFP 
(green). The dashed line depicts the boundary of the islet area. Scale bars are 
10µm. 
 
Treatment with Ig-GAD2+BM results in concomitant restoration of both β 
and endothelial cells in the islet of pancreas. 
The question then is whether the GFP+ engraftment represents cells that could 
not be provided by the host’s BM but are required for maintenance of 
endogenous β-cells. It is known that normal islet endothelial network is essential 
for optimal β-cell development and function (Cleaver and Melton, 2003; Lammert 
et al., 2001). For example, β-cells are in direct contact with the basement 
membranes of endothelial cells and islet endothelium is able to stimulate β-cell 
proliferation by secreting several factors (Johansson et al., 2006; Kaido et al., 
2004; Nikolova et al., 2006). Furthermore, the diabetic course is tightly 
associated with diminished numbers and impaired function of both EPCs in the 
bone marrow and mature ECs in the islet, leading to poor β-cell survival and 
maintenance (Caballero et al., 2007; Khoo et al., 2009; Loomans et al., 2004; 
Schatteman et al., 2000; Thum et al., 2007). In fact, in our NOD colony we 
detected a significant decrease in the frequency of both circulating and intra-islet 
PECAM1+ endothelial cells in diabetic mice relative to healthy or hyperglycemic 
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mice (Fig. 5). These results suggest that supplementation of BM cells provided 
factors that may correct the dysfunction of ECs in the diabetic NOD mice and 
generate a suitable microenvironment for optimal regulation of β-cell functions. 
  
 
 
 
Figure 5. Decline of blood and pancreatic endothelial cells during 
progression to diabetes. (A-B): Peripheral blood cells from un-manipulated 4-6 
week-old healthy (n=22), 8-14 week-old hyperglycemic (n=12) and 15-30 week-
old diabetic (n=9) mice were stained with anti-CD45, anti-PECAM1 and 7-AAD, 
and PECAM1 expression was analyzed on 7-AAD−CD45− gated cells. (A) shows 
representative FACS plots and (B) shows results of individually tested mice in 
each group. (C-D) Non-serial pancreatic sections from the same groups of mice 
were stained for insulin (green) and PECAM1 (red) and analyzed by 
immunofluorescence microscopy. (C) shows a representative staining within the 
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boundary of an islet area. Scale bars are 50µm. (D) shows the number of 
PECAM1+ cells per islet. This was determined by nuclear counterstaining with 
DAPI. At least 40 islets from 3-6 non-serial sections per mouse were analyzed. 
Each bar represents mean ± SEM of 5 mice per group. * P < 0.05, ** P < 0.01. 
To investigate the effects of the Ig-GAD2+BM treatment on islet ECs, we 
measured the amount of these cells in mice of each treatment group. The results 
show that there was a concomitant restoration of  insulin+ and PECAM1+ ECs in 
the islets of mice recipient of Ig-GAD2+BM but not in those given Ig-GAD2 or BM 
alone (Fig. 6A). Moreover, the recovering but not the untreated diabetic mice had 
a significant increase in the expression of genes encoding VE-cadherin (Cdh5), 
angiopoietin receptor (Tie1) and VEGF receptor 1 (Flt1) (Fig. 6B), which 
represent functional markers for ECs. These results indicate that during 
treatment with Ig-GAD2, the transfer of BM cells triggered angiogenic activities. 
This is supported by the detection of a strong up-regulation of genes encoding 
angiogenic factors, including VEGFa (vegfa), angiopoietin 1 (angpt1), and 
angiopoietin 2 (angpt2) in the diabetes-free mice treated by Ig-GAD2+BM (Fig. 
7A). Furthermore, the newly-formed β-cells produced VEGFa (Fig. 7B), which is 
critical for development of ECs and islet vascularization (Brissova et al., 2006; 
Lammert et al., 2003). The symbiotic relationship among endothelial and β cells 
is further evidenced by the parallel restoration of β-cell division in the Ig-
GAD2+BM cell transfer mice (Fig. 6C). Indeed, the β-cells displayed significant 
staining for the proliferation marker ki-67 when compared to resting β-cells in 
normal mice or to residual β-cells in untreated diabetic mice (Fig. 6C). Taken 
120 
 
together, these results suggest that BM transfer during treatment with Ig-GAD2 
re-established the functional endothelial network in the islet that ensured efficient 
regeneration of β-cells, and the newly-formed β-cells were able to produce the 
vital angiogenic factor VEGFa, which could further enhance the symbiotic 
relationship between the two cell types.  
 
 
Figure 6. Restoration of endothelial cells parallels with β-cell regeneration. 
(A) shows fluorescence microscopy images of PECAM1 (red) and insulin (green) 
immunostaining of pancreatic sections from mice given Ig-GAD2, BM or Ig-
GAD2+BM. Islet boundary is depicted by dashed lines. Scale bars are 50µm. 
The bar graph represents quantification of PECAM1+ cells per islet (5 mice per 
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group). 10-30 islets from 3-6 non-serial sections per mouse were examined. (B) 
Quantitative PCR analysis for cdh5, tie1 and flt1 expression in pancreatic islets of 
the mice described in (A) as well as untreated healthy and diabetic controls (4-8 
mice per group). (C) shows confocal microscopy images of insulin (green) and ki-
67 (red) staining of pancreatic sections from Ig-GAD2+BM treated mice (day 60 
of treatment),  healthy (untreated 4-6 week-old) and diabetic (day 1 of diagnosis) 
mice. The arrows depict insulin+ki-67+ cells. Scale bars are 10µm. The bar graph 
represents the number of insulin+ki-67+ cells per section. 30-40 non-serial 
sections from 6 mice per group were analyzed. The bars in the panels represent 
the mean ± SEM. * P < 0.05, ** P < 0.01. 
 
122 
 
 
 
Figure 7. Enhanced production of angiogenic factors during restoration of 
normoglycemia. (A) Diabetic mice were given Ig-GAD2+BM treatment regimen 
and RNA was extracted from their pancreata on day 60 and used to analyze 
expression of vegfa, angpt1 and angpt 2. RNA from the pancreata of healthy and 
diabetic mice was included for control purposes. Each bar represents relative fold 
change of gene expression (mean ± SEM) analyzed by quantitative PCR in 5 
mice per experimental group. (B) shows representative confocal microscopy 
visualizing VEGFa (green) and insulin (red) in pancreatic sections from Ig-
GAD2+BM-treated mice (sacrificed on day 60, n=3). At least 30 islets from 3-4 
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non-serial sections per mouse were analyzed. The scale bars are 10µm. * P < 
0.05, ** P < 0.01. 
 
Donor BM gave rise to islet endothelial cells.  
To determine whether the ECs in the islets originate from the donor BM, we 
examined the GFP+ cells for expression of PECAM1. Indeed, in the diabetes-free 
mice there were GFP+ cells in the islets that expressed PECAM1 as indicated by 
the colocalization of the two markers at both day 30 and 60 of treatment (Fig. 
8A). Such colocalization was not observed in mice recipient of the same regimen 
but remained diabetic. These observations are supported by the detection of Y 
chromosome in the endothelial but not β cells when BM cells were transferred 
from male donors. Indeed, Y chromosome was detectable when the DNA was 
extracted from bulk pancreatic cells in mice recipient of Ig-GAD2+BM (Fig. 8B). 
More specifically, when PECAM1+ and insulin+ cells were micro-dissected using 
a laser-capture system (Fig. 9) and their genomic DNA was analyzed by PCR, Y 
chromosome was readily detecable in PECAM1+ but not insulin+ cells and this 
was restricted to diabetes-free mice given Ig-GAD2+BM (Fig. 8, C and D). These 
results indicate that donor BM gives rise to endothelial cells that are required for 
recovery from diabetes.  
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Figure 8.  Donor bone marrow gives rise to pancreatic endothelial cells 
during suppression of diabetes. (A) shows confocal microscopy images for 
insulin (blue), PECAM1 (red) and GFP (green) from mice given Ig-GAD2 plus 
NOD.GFP BM (5 mice per time point). The arrows indicate co-localization of 
PECAM1 and GFP. Scale bars are 10µm. (B-D) PCR analysis of Y chromosome 
(Y) using genomic DNA extracted from raw pancreatic sections (B), micro-
dissected PECAM1+ (C) or insulin+ cells (D) of mice given Ig-GAD2+male BM 
(sacrificed on day 60 post treatment). DNA extracted from unmanipulated male 
(♂) and female (♀) mice was included for control purposes. In (C) lane 6 
represents DNA from a Ig-GAD2 + male BM-treated mouse that did not recover 
from diabetes. In (D) lanes 1-9 represent the percentage of male DNA diluted 
with female DNA. Lanes 10-12 represent DNA from three individual diabetes-free 
mice given Ig-GAD2 + male BM. 
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Figure 9. Microdissection of insulin+ or PECAM1+ cells. Pancreatic sections 
were stained for either insulin or PECAM1 (brown) and the cell nuclei were 
counterstained with hematoxylin (blue). Data shows representative light 
microscopy depicting the cell capture area before and after the procedure. The 
microdissected cells were then used for extraction of genomic DNA and PCR 
analysis.  
 
Transfer of purified BM EPCs sustained reversal of T1D during treatment 
with Ig-GAD2. 
The fact that EPCs are diminished in mouse and human diabetic subjects 
suggests that BM transfer during treatment with Ig-GAD2 serves as a source of 
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enrichment with EPCs. To test this premise, we first determined the frequency of 
EPCs in our NOD colony and found that the BM lineage-negative (Lin−) 
population expressing the EPC markers c-Kit (Dentelli et al., 2007) and FLK-
1(Peichev et al., 2000; Reyes et al., 2002) was significantly reduced in the 
diabetic versus age-matched healthy mice (Fig. 10, A and B). The Lin−c-Kit+FLK-
1+ population in healthy mice also expressed CD34 and AC133 (data not shown), 
further indicating their EPC phenotype (Peichev et al., 2000). We then sorted 
these EPCs from BM of healthy NOD.GFP mice and evaluated whether these 
cells can substitute whole BM for reversal of T1D. Importantly, when sorted 
GFP+Lin−c-Kit+FLK-1+ (hFLK-1+) cells from healthy donors replaced whole BM 
transfer during treatment with Ig-GAD2, most of the mice recovered from the 
disease while the control group given Lin−c-Kit+FLK-1− (hFLK-1−) cells had a 
much lower recovery rate despite receiving a 60-times higher cell number (Fig. 
10C). In addition, no significant recovery from disease was observed when the 
FLK-1+ cells were transferred without Ig-GAD2 (Fig. 10C). Because EPCs in 
diabetic subjects also displayed impaired ability to differentiate into functional 
endothelial cells, we next sought to determine whether enrichment of EPCs from 
diabetic donors would sustain the reversal of T1D during Ig-GAD2 treatment. 
Indeed, when sorted FLK-1+ cells from diabetic NOD.GFP mice (sFLK-1+) were 
transferred along with Ig-GAD2 treatment, there was minimal recovery of the 
disease (Fig. 10C). Collectively, these results suggest that enrichment of 
functional EPCs is essential for reversal of T1D during antigen-specific tolerance. 
Furthermore, GFP/PECAM1 colocalization was only detected in the islets of mice 
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given Ig-GAD2 and hFLK-1+ cells (Fig. 10D). The mice that did not recover from 
diabetes under the Ig-GAD2+hFLK-1− or Ig-GAD2+sFLK-1+ regimen had very 
few GFP+ and PECAM1+ cells with no evident colocalization similar to the mice 
recipient of hFLK-1+ cells without Ig-GAD2 (Fig. 10D). These results indicate that 
EPCs can substitute for BM transfer and give rise to mature ECs that help β-cells 
thrive and restore normoglycemia. Furthermore, maturation of the EPCs and 
increase in ECs occurs only when EPCs originate from healthy donors, which 
explains the inability of diabetic mice to utilize their own EPCs for repair of the 
pancreatic endothelial network.     
 
 
 
Figure 10. Transfer of endothelial cell progenitors during treatment with Ig-
GAD2 sustains β cell regeneration and restores normoglycemia. (A) shows 
representative FACS plots depicting FLK-1 expression on Lin−c-Kit+7-AAD− BM 
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cells from age-matched healthy and diabetic mice. (B) shows FLK-1 expression 
on Lin−c-Kit+7-AAD− BM cells of individually tested mice described in (A). (C-D) 
FACS-sorted Lin−c-Kit+FLK-1+ (FLK-1+) or Lin−c-Kit+FLK-1− (FLK-1−) BM cells 
from healthy (hFLK-1+) or diabetic (sFLK-1+) NOD.GFP donors were used with or 
without Ig-GAD2 for treatment of diabetic NOD mice. Some of the mice were 
monitored for diabetes for 100 days (C), and others (D) were sacrificed on day 60 
post treatment and used for visualizing insulin (blue), PECAM1 (red) and GFP by 
confocal microscopy (at least 20 sections per group). The arrows indicate co-
localization of PECAM1 and GFP. Scale bars are 10µm. ** P < 0.01. 
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DISCUSSION 
Recent advances have shown that treatment with anti-CD3 antibody can reverse 
overt diabetes (Chatenoud and Bluestone, 2007; Waldron-Lynch and Herold, 
2011). However, because of potential interference with the function of the 
immune system, open-ended treatment regimens are undesirable (Luo et al., 
2010). In this context, antigen-specific approaches (Agardh et al., 2005; Gregg et 
al., 2005; Gregg et al., 2004; Michels and von Herrath, 2011; Tian et al., 1996; 
Tisch et al., 1998) which target autoreactive T cells and circumvent interference 
with immunity provide an alternative that could be effective against the disease. 
We and others have tested cell or protein-based antigen-specific regimens at 
advanced stages of the disease and promising outcomes were observed (Jain et 
al., 2008; Li et al., 2009; Tang et al., 2004).  In fact, Ig-GAD2 was able to trigger 
β-cell regeneration which prevented progress to overt diabetes (Jain et al., 2008).  
The present study was designed to test Ig-GAD2 for efficacy against overt T1D. 
However, despite the induction of an immune modulation similar to the 
hyperglycemic stage, the regimen was not able to trigger β-cell regeneration or 
overcome overt T1D. Given that β-cells are able to self renew (Dor et al., 2004) 
we thought that either the differentiation of stem cell progenitors into insulin-
producing β-cells is defective at this stage of the disease or there was minimal 
residual β-cells to support division and formation of sufficient β-cell mass. 
Although the use of BM as a source of β cell progenitors is debatable (Choi et al., 
2003; Hess et al., 2003; Ianus et al., 2003; Lechner et al., 2004; Mathews et al., 
2004), repair of injured islet was feasible by BM transplantation (Hess et al., 
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2003; Mathews et al., 2004). Thus, we supplemented Ig-GAD2 treatment with 
BM transfer and found that recovery from disease is attainable. This was 
intriguing and prompted us to determine the mechanism underlying restoration of 
normoglycemia. Interestingly, the islets had increased β-cell mass but the 
proliferating insulin-producing cells were of endogenous origin rather than donor 
BM-derived cells. Surprisingly, alongside the newly formed β-cells there was 
engraftment of donor BM-derived cells that did not produce insulin or colocalize 
with the β cells.  
It has previously been shown in human patients with recent onset of T1D that the 
number of EPCs is significantly reduced in the peripheral blood compared with 
sex-matched healthy control subjects (Loomans et al., 2004; Schatteman et al., 
2000). More importantly, EPCs in these patients displayed impaired migratory 
capacity (Thum et al., 2007) and damage repair potential (Caballero et al., 2007), 
and failed to differentiate into functional vasculatures (Loomans et al., 2004; 
Schatteman et al., 2000). Given that our NOD mice displayed diminished 
frequency of EPCs at the onset of diabetes as was observed by others (Khoo et 
al., 2009; Schatteman et al., 2000), we suspected that the engrafted donor BM-
derived cells represent mature ECs. This was indeed the case as the BM-derived 
GFP cells present in the islets of treated diabetes-free mice expressed the EC 
marker PECAM1. Moreover, PECAM1 expression tightly colocalized with donor 
GFP but not with newly formed endogenous β-cells. Since recovery from 
diabetes occurred only when the treatment is accompanied with BM transfer it is 
likely that repair of the islet vascular system was required to maintain symbiosis 
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among β and ECs (Brissova et al., 2006; Cleaver and Melton, 2003; Guney et al., 
2011; Johansson et al., 2006; Kaido et al., 2004; Lammert et al., 2001; Nikolova 
et al., 2006). This could explain the unexpected engraftment of donor BM-derived 
endothelial cells in the pancreas of STZ mouse models of experimental diabetes 
(Hess et al., 2003; Mathews et al., 2004) especially since the animals have 
undergone irradiation prior to BM transplantation which destroys endogenous 
stem cell precursors. The fact that β-cells produced VEGFa and the angiogenic 
activity in the pancreas became evident, it is likely that repair of the islet vascular 
niche is required for β-cells to thrive and for insulin delivery into the circulation. 
Along this line of reasoning we substituted whole BM with EPCs (Lin−c-Kit+FLK-
1+) during treatment with Ig-GAD2 and observed formation of donor-derived ECs 
alongside the generation of endogenous β-cells in the diabetes-free mice. Again, 
this suggests that under tight control of the immune inflammatory process, the 
symbiotic relationship between β and ECs ensues and both types of cells 
contribute to the makeup of an environment suitable for formation of β-cells, 
maturation of ECs, and maintenance of healthy islets. Studies with anti-CD3 
antibody indicated that despite control of the inflammatory process β-cell 
proliferation/regeneration was minimal or at a very slow rate (Ablamunits et al., 
2007; Phillips et al., 2007; Takiishi et al., 2012) with evident re-granulation of 
residual insulin-negative β cells (Ablamunits et al., 2007). However, when 
eradication of inflammation was accompanied with exogenous epidermal growth 
factor (EGF), β cell neogenesis and proliferation ensued and sustained reversal 
of overt T1D (Wang et al., 2012). The findings in our study suggest that the low 
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frequency of EPC and the defective function of residual pancreatic endothelial  
network  in diabetics compromise not only the generation of new β-cells but also 
the restoration of optimal function, hence the  return of disease observed in 
human trials upon termination of anti-CD3 antibody treatment (Herold et al., 
2005; Herold et al., 2002). In summary, antigen-specific therapy and 
supplementation with EPCs may overcome the limitation associated with long-
term antibody administration and the repair of the islet endothelial niche. Whether 
effective control of immune inflammation by multiple Ig chimeras and diverse 
mechanisms (Gregg et al., 2005; Gregg et al., 2004; Jain et al., 2008; Tartar et 
al., 2010; Wan et al., 2012) upon early diagnosis of disease would overcome the 
need for stem cell enrichment remains to be determined. 
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